<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K/A
(Amendment No.1)
(Mark One)
[X] Annual report pursuant to section 13 or 15(d) of the Securities Exchange
Act of 1934 For the fiscal year ended December 31, 1998
OR
[_] Transition report pursuant to section 13 or 15(d) of the Securities
Exchange Act of 1934
For the transition period from to
Commission File Number 0-19651
MAGAININ PHARMACEUTICALS INC.
(Exact name of registrant as specified in its charter.)
Delaware 13-3445668
(State or other jurisdiction of (IRS Employer
incorporation or organization) Identification No.)
5110 Campus Drive, Plymouth Meeting, PA 19462
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (610) 941-4020
SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT:
None N/A
(Title of each class) (Name of each exchange on which registered)
SECURITIES REGISTERED PURSUANT TO SECTION 12(g) OF THE ACT:
Common Stock, $.002 par value per share
(Title of Class)
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports) and (2) has been subject to such
filing requirements for the past 90 days. YES [X] NO [_]
Indicate by check mark if disclosure of delinquent filers pursuant to Item
405 of Regulations S-K is not contained herein, and will not be contained, to
the best of registrant's knowledge, in definitive proxy or information
statements incorporated by reference in Part III of this Form 10-K or any
amendment to this Form 10-K. [X]
The aggregate market value of the voting stock held by non-affiliates of
the registrant is approximately $97,843,000. Such aggregate market value was
computed by reference to the closing price of the Common Stock as reported on
the National Market System of The Nasdaq Stock Market, on February 22, 1999. For
purposes of this calculation only, the registrant has defined affiliates as
including all directors and executive officers. The number of shares of the
registrant's Common Stock outstanding as of February 22, 1999 was 22,911,616.
The purpose of Ammendment No. 1 is to file Exhibits 10.32, 10.33 and 10.34.
1
<PAGE>
ITEM 14. EXHIBITS, FINANCIAL STATEMENT SCHEDULES AND REPORTS ON FORM 8-K
Financial Statements
The information required by this item was previously filed.
Financial Statement Schedules
All schedules have been omitted because they are not applicable, or not
required, or the information is shown in the Financial Statements or Notes
thereto.
Reports on Form 8-K
None.
2
<PAGE>
Exhibits
The following is a list of exhibits filed as part of this Amendment No. 1
on Form 10-K/A. Where so indicated by footnote, exhibits which were previously
filed are incorporated by reference. For exhibits incorporated by reference, the
location of the exhibit in the previous filing is indicated parenthetically,
together with a reference to the filing indicated by footnote.
Exhibit No.
- -----------
3.1 Restated Certificate of Incorporation of the Registrant (Exhibit
3.1)(1)
3.2 Certificate of Amendment of Restated Certificate of Incorporation of
the Registrant (Exhibit 3.2)(13)
3.3 By-laws of the Registrant (Exhibit 3.2)(2)
4.1 Specimen copy of stock certificate for shares of Common Stock of the
Registrant (Exhibit 4.1)(3)
10.1# 1990 Stock Option Plan of the Registrant (Exhibit 10.1)(2)
10.2# 1992 Stock Option Plan of the Registrant, as amended (4)
10.3# Stock Option Agreement with Jay Moorin (Exhibit 10.24)(3)
10.4# Amendment to Stock Option Agreement with Jay Moorin (Exhibit 10.4)(1)
10.5# Form of Stock Option Agreement under Stock Option Plans (Exhibit
4.6)(2)
10.6# Employment Agreement with Jay Moorin (Exhibit 10.2)(2)
10.7# Employment Agreement with Michael A. Zasloff (Exhibit 10.23)(3)
10.8# Amendment of Employment Agreement with Michael A. Zasloff, M.D.,
Ph.D. (Exhibit 10.9)(3)
10.9# Employment Agreement with Michael R. Dougherty (Exhibit 10.26)(7)
10.10# Employment Agreement with Roy C. Levitt, M.D. (Exhibit 10.24)(5)(9)
10.11# Employment Agreement with Thomas J. Bigger (Exhibit 10.12)(13)
10.12#* Employment Agreement with Kenneth J. Holroyd, M.D.
10.13#* Consulting Agreement with Jay Moorin, dated August 3, 1998
10.14 Lease with respect to Plymouth Meeting, Pennsylvania offices and
laboratories (Exhibit 10.16)(2)
3
<PAGE>
10.15 Lease with respect to Plymouth Meeting, Pennsylvania office (Exhibit
10.13)(14)
10.16* Ammendment to lease with respect to Plymouth Meeting, Pennsylvania
offices and laboratories
10.17 Patent License Agreement and Sponsored Research Agreement with The
Children's Hospital of Philadelphia (Exhibit 10.15)(2)
10.18 License Agreement with Multiple Peptide Systems, Inc. (Exhibit
10.12)(2)
10.19 Second Amendment to License Agreement with Multiple Peptide Systems,
Inc. (Exhibit 10.30)(12)
10.20 Stock Issuance Agreement between Magainin Pharmaceuticals, Inc. and
The Scripps Research Institute. (Exhibit 10.2)(11)
10.21 Stock Issuance Agreement between Magainin Pharmaceuticals, Inc. and
Houghten Pharmaceuticals, Inc. (Exhibit 10.1)(11)
10.22 Form of Credit Agreement, including form of Promissory Note and
Warrant (Exhibit 10.22)(2)
10.23 Form of Amendment to Credit Agreement Warrant (Exhibit 10.18)(6)
10.24 Research and Development Agreement with Abbott Laboratories (Exhibit
10.23)(7)
10.25 Warrant Agreement with Abbott Laboratories (Exhibit 10.25)(7)
10.26 Manufacturing Agreement with Abbott Laboratories, dated October 4,
1995 (Exhibit 10.27)(5)(8)
10.27 Stock Issuance Agreement with Abbott Laboratories, dated October 4,
1995 (Exhibit 10.28)(5)(8)
10.28 Assignment Agreement between Magainin Pharmaceuticals Inc., Roy C.
Levitt, M.D. and GeneQuest, Inc. (Exhibit 10.25)(5)(9)
10.29 Form of Purchase Agreement relating to the issuance by Magainin
Pharmaceuticals, Inc. of units consisting of shares of Magainin
Pharmaceuticals, Inc. Common Stock and warrants to purchase shares of
Common Stock. (Exhibit 10.1)(10)
10.30 Form of Warrant to purchase shares of Magainin Pharmaceuticals, Inc.
Common Stock. (Exhibit 10.2)(10)
10.31 Development, Supply and Distribution Agreement, effective as of
February 12, 1997 with SmithKline Beecham Corporation (Exhibit
10.29)(5)(13)
4
<PAGE>
10.32+ Collaborative Research and Option Agreement with Genentech, Inc.,
effective as of December 30, 1998 (16)
10.33+ Stock Purchase Agreement between Magainin Pharmaceuticals, Inc. and
Genentech Inc., dated December 30, 1998 (16)
10.34+ Supply Agreement between Abbott Laboratories Inc. and Magainin
Pharmaceuticals, Inc., effective January 1, 1999 (16)
10.35# 1998 Equity Compensation Plan (15)
10.36#* Form of stock award letter under 1998 Equity Compensation Plan
23* Consent of KPMG LLP
24* Power of Attorney (included on signature page of this Annual Report
on Form 10-K)
27* Financial Data Schedule
Explanation of Footnotes to Listing of Exhibits
* Previously filed.
# Compensation plans and arrangements for executives and others.
+ Filed herewith.
(1) Filed as an Exhibit to the Annual Report on Form 10-K for the year ended
June 30, 1992 filed with the Securities and Exchange Commission on
September 24, 1992.
(2) Filed as an Exhibit to Registration Statement (No. 33-43579) on Form S-1
filed with the Securities and Exchange Commission on October 24, 1991.
(3) Filed as an Exhibit to Pre-Effective Amendment No. 1 to Registration
Statement (No. 33-43579) on Form S-1 filed with the Securities and
Exchange Commission on November 27, 1991.
(4) Filed as Exhibit A to the Proxy Statement for the 1996 Annual Meeting of
Stockholders.
(5) Portions of this Exhibit were omitted and filed separately with the
Securities and Exchange Commission pursuant to an order granting
confidential treatment.
(6) Filed as an Exhibit to the Transition Report on Form 10-K for the year
ended December 31, 1993 filed with the Securities and Exchange Commission
on March 9, 1994.
5
<PAGE>
(7) Filed as an Exhibit to the Annual Report on Form 10-K for the year ended
December 31, 1994 filed with the Securities and Exchange Commission on
March 31, 1995.
(8) Filed as an Exhibit to the Form 10-Q for the quarter ended September 30,
1995 filed with the Securities and Exchange Commission on November 9,
1995.
(9) Filed as an Exhibit to the Annual Report on Form 10-K for the year ended
December 31, 1995 filed with the Securities and Exchange Commission on
March 29, 1996.
(10) Filed as an Exhibit to Registration Statement (No. 333-09927) on Form S-3
filed with the Securities and Exchange Commission on August 9, 1996.
(11) Filed as an Exhibit to Registration Statement (No. 333-14555) on Form S-3
filed with the Securities and Exchange Commission on October 21, 1996.
(12) Filed as an Exhibit to the Form 10-Q for the quarter ended September 30,
1996 filed with the Securities and Exchange Commission on November 14,
1996.
(13) Filed as an Exhibit to the Annual Report on Form 10-K for the year ended
December 31, 1996 filed with the Securities and Exchange Commission on
March 31, 1997.
(14) Filed as an Exhibit to the Annual Report on Form 10-K for the year ended
December 31, 1997, filed with the Securities and Exchange Commission on
March 13, 1998.
(15) Filed as Exhibit A to the Proxy Statement for the 1998 Annual Meeting of
Stockholders.
(16) Portions of the Exhibit have been omitted and have been filed separately
pursuant to an application for confidential treatment filed with the
Securities and Exchange Commission pursuant to Rule 24b-2 under the
Securities Exchange Act of 1934, as amended.
6
<PAGE>
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
MAGAININ PHARMACEUTICALS INC.
By: /s/ Michael R. Dougherty
-----------------------------
Michael R. Dougherty
President, Chief Executive Officer,
Chief Financial Officer and Director
Date: March 19, 1999
7
<PAGE>
EXHIBIT INDEX
The Exhibits that have been filed herewith this Form 10-K/A are summarized
as follows:
Exhibit No. Description
- ----------- -----------
10.32* Collaborative Research and Option Agreement with Genentech, Inc.,
effective as of December 30, 1998
10.33* Stock Purchase Agreement between Magainin Pharmaceuticals, Inc. and
Genentech Inc., dated December 30, 1998
10.34* Supply Agreement between Abbott Laboratories Inc. and Magainin
Pharmaceuticals, Inc., effective January 1, 1999
Explanation of Footnotes to Listing of Exhibits
* Portions of the Exhibit have been omitted and have been filed
separately pursuant to an application for confidential treatment
filed with the Securities and Exchange Commission pursuant to Rule
24b-2 under the Securities Exchange Act of 1934, as amended.
8
<PAGE>
EXECUTION COPY
--------------
* The confidential material contained herein has been omitted and filed
separately wth the Commission.
COLLABORATIVE RESEARCH AND OPTION AGREEMENT
December 30, 1995
THIS COLLABORATIVE RESEARCH AND OPTION AGREEMENT ("Agreement") is made
as of the date first written above ("Effective Date") by and between Magainin
Pharmaceuticals Inc., a Delaware corporation, having a place of business at 5110
Campus Drive, Plymouth Meeting, Pennsylvania 19462 ("Magainin") and Genentech
Inc., a Delaware corporation having a place of business at 1 DNA Way South San
Francisco, California 94080 ("Genentech").
RECITALS
WHEREAS, Magainin has undertaken certain research efforts relating to
the role of IL-9 in asthma, and
WHEREAS, Genentech desires to conduct research to determine the role of
IL-9 in reducing the symptoms of asthma, and
WHEREAS, Genentech desires to receive from Magainin an exclusive option
to negotiate a development and commercialization agreement, and
WHEREAS, Magainin is interested in providing such an option to
Genentech,
NOW, THEREFORE, in consideration of the premises and mutual covenants
contained herein, and intending to be legally bound hereby, the Parties hereto
agree as follows:
1 DEFINITIONS
1.1 "Compound" shall mean a protein that directly or indirectly
----------
inhibits the production, action or effect of IL-9.
1.2 "Field" shall mean the prevention or treatment of human asthma
-------
and bronchial hyperresponsiveness by the therapeutic use of a Compound.
1.3 "Know-How" shall mean information, expertise and intellectual
----------
property that relates to Compound
1.5 "Licensed Patent Rights" shall mean all current and future
------------------------
patents and patent applications throughout the world (including all extensions,
substitutions, reissues, and reexaminations of the foregoing) having claims
directed to any Compound in the Field (a) that Magainin owns (in whole or in
part) or controls and has the right to license or sublicense or (b) that result
from research performed under the Research Plan.
1.6 "Reagents" shall mean reagents listed in Appendix B.
---------- ----------
<PAGE>
1.7 "Research" shall mean research work of the Parties on Compound.
----------
1.8 "Research Plan" shall mean the research plan attached to this
---------------
Agreement as Appendix A.
1.9 "Research Term" shall mean the period of time commencing upon
---------------
the Effective Date and terminating on December 31, 1999, unless the affinity of
Magainin's antibody is found to be worse than that specified in Research Plan,
in which case, the Parties agree to mutually extend the Research Term.
1.10 "Results" shall mean any and all materials, information,
---------
discoveries, ideas, Know-How, data and techniques that are made, created or
reduced to practice in the course of, or as a result of, the Research.
1.11 "Stock Purchase Agreement" shall mean the agreement attached as
--------------------------
Appendix C.
- ----------
1.12 "Third Party" shall mean any person other than a Party to this
-------------
Agreement.
2. RESEARCH
2.1 Research Plan - During the Research Term, Magainin and
-------------
Genentech shall jointly conduct Research pursuant to the Research Plan.
Each of the Parties shall allocate sufficient resources,
including, without limitation, personnel, equipment, supplies, reagents and
facilities, to conduct Research as set forth in the Research Plan. Each Party
shall be responsible for its own expenses and costs incurred under the Research
Plan.
Magainin shall provide to Genentech at no cost reasonable
quantities of Reagents that may be requested from time to time under the
Research Plan.
2.2 Exclusive Research Relationship - During the Research Term,
-------------------------------
neither Party may conduct research on Compound with any Third Party without the
prior written consent of the other Party.
2.3 Intellectual Property - All patents and patent applications that
---------------------
result from sole Genentech inventions under the Research Plan, shall be
exclusively owned by Genentech. Any joint inventions shall be owned by the
Parties jointly. All title and interest in any Results obtained by Genentech
under the Research Plan will belong to Genentech, although Genentech shall
provide Magainin free access to and use of Results. If for any reason the
Parties do not enter into a research and development agreement as contemplated
by Section 3.1 hereof, Genentech shall negotiate in good faith with Magainin to
grant Magainin a license for any
2
<PAGE>
Genentech intellectual property developed under the Research Plan either solely
or jointly with Magainin.
3. OPTION
3.1 Option Grant - Magainin hereby grants to Genentech an exclusive
------------
option to enter into an agreement to develop and commercialize any and all
Compounds in the Field, exercisable for one hundred twenty (120) days after the
end of the Research Term. Such agreement shall include: (a) the grant by
Magainin to Genentech of an exclusive worldwide sublicensable license (the
"License") under Magainin's Licensed Patent Rights and Know-How to make, have
made, use, sell, offer for sale and import Compound in the Field; (b) maximum
aggregate payments by Genentech under such agreement for any signing fee,
sponsored research and development, development and approval milestones, and all
other payments of any form except royalties, shall not exceed $35.0 million,
which may be paid in one or more of the following forms, a loan, equity
investment pursuant to the terms of the Stock Purchase Agreement or cash; and
(c) a royalty of up to ()% of net sales of Compound in the Fields prior to *
Third Party royalty offsets to be negotiated. The precise royalty to be agreed
upon will depend on the relative intellectual property contribution (both Know-
How and patents) of Magainin to the development and commercial exclusivity of a
Compound in the Field. The Parties have discussed Genentech's standard deal
structure of off balance sheet financing and back-end loaded deals weighted
toward approval milestones. The Parties recognize that the final negotiated deal
must be fair to both Parties consistent with the facts (e.g., scope of
collaboration contemplated) and data (e.g., Research Plan results) available at
the time of the negotiation and conform to the broad deal outline and structure
noted above The Parties agree to negotiate in good faith the other terms of such
development and commercialization agreement.
Magainin shall notify Genentech of any serious negotiations with
Third Parties involving
( ) *
in the prevention or treatment of human asthma and bronchial
hyperresponsiveness, and will negotiate in good faith with Genentech to enter
into a collaboration in such area.
3.2 Equity Purchase - Genentech shall make an equity investment in
---------------
Magainin as provided for in the Stock Purchase Agreement.
4. LICENSES
4.1 License Grant - During the Research Term, and only to the extent
-------------
necessary to conduct its activities under the Research Plan,. Magainin grants to
Genentech a license under Licensed Patent Rights and Know-How in the Field
3
* THE CONFIDENTIAL MATERIAL CONTAINED
HEREIN HAS BEEN OMITTED AND HAS BEEN
FILED SEPARATELY WITH THE COMMISSION
<PAGE>
5. FUTURE RIGHTS
5.1 To the extent Magainin obtains rights to a Compound outside of
the Field, and Genentech wishes to collaborate with Magainin, Magainin agrees to
negotiate in good faith with Genentech to enter into a collaboration in such
area.
6. TERM AND TERMINATION
6.1 Term - The Agreement shall commence upon the Effective Date and
----
shall expire at the end of the Research Term, unless extended by the written
agreement of the Parties.
6.2 Termination - Genentech may terminate this Agreement at any time
-----------
during the Research Term upon thirty (30) days written notice to Magainin
Upon the termination of the Agreement, all licenses granted to
Genentech shall terminate.
7. CONFIDENTIAL INFORMATION, PUBLICITY
7.1 Requirement of Confidentiality -- This Agreement contemplates
------------------------------
the exchange of certain confidential and proprietary information by one Party
(the "Disclosing Party") to the other Party (the "Receiving Party") during the
term of this Agreement (the "Confidential Information) and the development of
certain confidential and proprietary information in the course of the
collaboration by the Parties hereunder, including, without limitation, Know-How
and Results (the "Research Information") (the Confidential Information and
Research Information are collectively referred to hereinafter as the
"Information"). With respect to the Information, each Party, shall:
(a) use such Information only for the purpose of
performing its duties or exercising its rights under this Agreement
and for no other purpose, subject to the terms and conditions of this
Agreement;
(b) safeguard such Information against disclosure to
others with the same degree of care as it exercises with its own data
of a similar nature, but not less than a reasonable degree of care;
and
(c) not disclose such Information to others (except to its
employees, or consultants, who are bound to the Receiving Party by a
like obligation of confidentiality and restriction on use) without
the express written consent of the other Party.
4
<PAGE>
7.2 Confidential Information - The commitments set forth in Section
------------------------
7.1 shall be of five (5) years' duration from date of disclosure and shall not
impose any obligation upon a Party with respect to any portion of the
Information which such Patty can establish:
(a) Was known to the Receiving Party prior to the receipt of the
same directly or indirectly from the Disclosing Party; or
(b) Is now, or becomes in the figure, public knowledge other
than through acts or omissions of the Receiving Party; or
(c) Is disclosed at any time to the Receiving Party by a Third
Party that had a lawful right to disclose it; or
(d) Is subsequently developed by either Party independent of the
Information received hereunder; or
(e) Has been or is subsequently disclosed by the Disclosing
Party to any Third Party on a non-confidential basis.
7.3 Publicity and News Releases -- Except as may be required by
---------------------------
applicable laws, rules or regulations, neither Party will originate any
publicity, news release, or other public announcement, written or oral, whether
to the public press or otherwise, relating to any amendment hereto or to
performance hereunder or the existence of this Agreement or an arrangement
between the Parties relating to this Agreement, without the prior written
approval of the other Party. In the event disclosure is required by applicable
law, rules or regulations, then the Party required to so disclose such
information shall, to the extent possible, provide to the other Party for its
approval (such approval not to be unreasonably withheld), a written copy of such
public announcement at least five (5) business days prior to disclosure.
Notwithstanding the foregoing, Magainin shall have the right to make a press
release with respect to its entering into this Agreement. Magainin shall provide
to Genentech a copy of the proposed press release no less than three (3)
business days prior to its proposed release. The contents of such press release
shall be subject to Genentech's consent, such consent not to be unreasonably
withheld.
8 MISCELLANEOUS
8.1 Entire Agreement Amendment - This Agreement, together with the
--------------------------
Stock Purchase Agreement attached hereto as Appendix C and the documents
----------
contemplated thereby, constitute the entire Agreement between the Parties
relating to the subject matter hereof and supersede all previous writings and
understandings whether oral or written, relating to such subject matter. This
Agreement may not be amended, supplemented or otherwise modified except by an
instrument in writing signed by both Parties that specifically refers to this
Agreement.
5
<PAGE>
8.2 Notices -- Any notice or other communication required or
-------
permitted under this Agreement shall be sent by certified mail or courier
service, charges prepaid, or by facsimile transmission, to the address or
facsimile number specified below:
If to Magainin:
Magainin Pharmaceuticals Inc
5110 Campus Drive
Plymouth Meeting, PA 19462
Fax No: 610-941-5399
Attention: Corporate Secretary
If to Genentech:
Genentech, Inc
1 DNA Way
South San Francisco, CA 94080
Fax No: 650-952-9881
Attention: Corporate Secretary
or to such other address or facsimile number as the person may specify in a
notice duly given to the sender as provided herein. A notice will be deemed to
have been given upon its deposit in the United States mail or with a courier
service, or, in the case of facsimile transmission, upon machine confirmation
that such transmission has been received.
8.3 Headings and Reference -- All section headings contained in this
----------------------
Agreement are for convenience of reference only and shall not affect the meaning
or interpretation of this Agreement. Unless the context requires otherwise, all
references in this Agreement to any section, exhibit or appendix shall be deemed
and construed as reference to a section of, or an exhibit or appendix to, this
Agreement, any such exhibits and appendices are hereby incorporated in this
Agreement by such reference.
8.4 Assignment and Binding Effect -- This Agreement and the licenses
-----------------------------
herein granted shall be binding upon and inure to the benefit of the successors
and assigns of the Parties hereto. Neither Party may assign any of its rights,
or delegate any of its obligations, under this Agreement without the written
consent of the other Party. Notwithstanding the foregoing, either Party may,
without obtaining the consent of the other Party, assign this Agreement to any
Affiliate or to any corporation with which it may merge or consolidate, or to
which it may transfer all or substantially all of its assets to which this
Agreement relates.
8.5 Severability -- In the event that any provision of this
------------
Agreement shall be held illegal, void or ineffective, the remaining portions
hereof shall remain in full force and effect so long as such remaining portions
do not materially change the intent of this Agreement or the right or
obligations of the Parties hereunder. If any provision of this Agreement is in
conflict with any applicable statute or law in any jurisdiction, then such
provision shall be
6
<PAGE>
deemed inoperative in such jurisdiction to the extent of such conflict and the
Parties will renegotiate the affected provisions of this Agreement to resolve
any inequities. It is the intention of the Parties that, if any court or other
tribunal construes any provision or clause of this Agreement, or any portion
thereof, to be illegal, void or unenforceable because of the duration of such
provision or the area or matter covered thereby, such court shall reduce the
duration, area or matter of such provision and enforce such provision in its
reduced form.
8.6 No Conflicts -- Each Party represents and warrants to the other
------------
that it has the lawful right to enter into and perform its obligations under
this Agreement, and that the terms of the Agreement do not conflict with any
other obligations of such Party.
8.7 Governing Law - This Agreement shall be governed in all respects
-------------
by the laws of the State of New York applicable to contracts between New York
residents entered into and to be performed entirely within the State of New
York.
8.8 Counterparts; Facsimile -- This Agreement may be executed in any
-----------------------
number of counterparts and by facsimile, each of which may be executed by fewer
than all of Parties hereto, each of which shall be enforceable against the
Parties actually executing such counterparts, and all of which together shall
constitute one instrument.
[signature page follows]
7
<PAGE>
IN WITNESS WHEREOF, the Parties, through their authorized officers, have
duly executed this Agreement as of the date first written above.
MAGAININ PHARMACEUTICALS INC GENENTECH, INC.
By: /s/ Michael R. Dougherty By: /s/ W. D. Young
--------------------------- ------------------------------
Name: Michael R. Dougherty Name: William D. Young
Title: President and Chief Title: Chief Operating Officer
Executive Officer
<PAGE>
APPENDIX A
----------
Genentech Program to Evaluate the Role of IL-9 in Murine Asthma
***
1
* THE CONFIDENTIAL MATERIAL CONTAINED
HEREIN HAS BEEN OMITTED AND HAS BEEN
FILED SEPARATELY WITH THE COMMISSION
<PAGE>
Appendix B
Reagent List 12-29-98
---------------------
***
* THE CONFIDENTIAL MATERIAL CONTAINED
HEREIN HAS BEEN OMITTED AND HAS BEEN
FILED SEPARATELY WITH THE COMMISSION
<PAGE>
* The confidential material contained herein has been omitted and filed
separately with the Commission.
EXECUTION COPY
--------------
MAGAININ PHARMACEUTICALS INC.
COMMON STOCK PURCHASE AGREEMENT
December 30, 1998
THIS COMMON STOCK PURCHASE AGREEMENT (this "Agreement") is made as of
the date hereof by and between MAGAININ PHARMACEUTICALS INC., a Delaware
corporation (the "Company") having its principal executive office at 5110 Campus
Drive, Plymouth Meeting, Pennsylvania 19462, and GENENTECH, INC, a Delaware
corporation having its principal executive office at 1 DNA Way, South San
Francisco, California 94080 (the "Investor").
RECITALS
WHEREAS, the Company and the Investor are contemporaneously entering
into a Collaborative Research and Option Agreement (the "Option Agreement"),
pursuant to which the Investor will conduct research with respect to IL-9 and
the Company will grant the Investor an exclusive option to enter into an
agreement regarding the development and commercialization thereof; and
WHEREAS, pursuant to the Option Agreement the parties have agreed to
enter into this Agreement; and;
WHEREAS, the Company has authorized the sale and issuance of such
number of shares of its Common Stock, par value $.002 per share (the "Common
Stock"), as may be issued and sold pursuant to this Agreement (the "Shares");
and
WHEREAS, the Investor desires to purchase the Shares on the terms and
conditions set forth herein; and
WHEREAS, the Company desires to issue and sell the Shares to the
Investor on the terms and conditions set forth herein; and
WHEREAS, the Shares shall have registration rights as evidenced by the
Registration Rights Agreement in the form attached hereto (the "Registration
Rights Agreement");
NOW, THEREFORE, in consideration of the foregoing recitals and the
mutual promises hereinafter set forth,
THE PARTIES HEREBY AGREE AS FOLLOWS:
1. Purchase and Sale of Stock.
--------------------------
1.1 Sale and Issuance of Common Stock. Subject to the terms
---------------------------------
and conditions of this Agreement, the Company hereby agrees to sell and
issue to the Investor, and the Investor hereby agrees to purchase from
the Company, that number of Shares set forth opposite the Investor's
name on Exhibit A hereto at the per share purchase price equal to one
---------
hundred ten percent (110%) of the arithmetic average of the last sale
price of one share of the Common Stock on the twenty
<PAGE>
(20) trading days immediately prior to the date of the Closing (as
defined below), as reported on the Nasdaq National Market (the "Per
Share Purchase Price").
1.2 Initial Closing. The purchase and sale of the Shares
---------------
representing an aggregate consideration of Two Million Dollars
($2,000,000.42) of the Common Stock shall take place at the offices of
Genentech, Inc., 1 DNA Way, South San Francisco, California 94080 (the
"Genentech Offices"), at 10:00 a.m. California time on date hereof, or
such other date and time as the Company and the Investor mutually agree
orally or in writing (which time and place are designated as the
"Initial Closing").
1.3 Contingent Subsequent Closings. In connection with the
------------------------------
Investor's exercise of its option (the "Option") granted pursuant to
Section 3.1 of the Option Agreement, the Investor shall have the
option, if agreed to by the Company, to purchase additional Shares of
Common Stock pursuant to an agreement substantially in the form hereof,
and the Company shall issue and sell such additional Shares to the
Investor at one or more additional closings as may be agreed by the
parties, at a price and subject to terms mutually agreed upon by the
parties pursuant to this Agreement or such other agreement (such times
and place are each designated as a "Subsequent Closing"). When used
herein, the term "Closing", refers to the Initial Closing or each of
the Subsequent Closings, as applicable. The parties shall update
Exhibit A hereto with each Subsequent Closing, if any, made pursuant to
---------
this Agreement.
1.4 Delivery. At the Closing, the Company shall deliver to the
--------
Investor a certificate registered in the Investor's name representing
the Shares to be purchased by the Investor. Such delivery shall be
against payment of the purchase price therefore in an amount equal to
the product of the number of Shares and the Per Share Purchase Price by
wire transfer to the Company's bank account at
Bank Name: First Union National Bank
Bank Address: FC 3-90-1-3
2240 Butler Pike
Plymouth Meeting, PA 19462
Bank Contact John Berardinelli
ABA#: 031-2014-67
Account Name: Magainin Pharmaceuticals Inc.
Account Number: ( ) *
2. Representations and Warranties of the Company. Except as set
---------------------------------------------
forth in the Company's Annual Report on Form 10-K for the year ending December
31, 1997, and Quarterly Report on Form 10-Q as of September 30, 1998, or as set
forth on the Schedule of Exceptions attached hereto as Exhibit B, the Company
---------
hereby represents and warrants, to the best of the Company's knowledge and
belief, as follows:
2.1 Organization, Good Standing and Qualification. The Company
---------------------------------------------
is a corporation duly organized, validly existing and in good standing
under the laws of the State of Delaware and has all requisite corporate
power and authority to own and operate its properties and assets, and
to carry on its business as currently conducted and as proposed to be
conducted. The Company is duly qualified to transact business and is in
good standing in each jurisdiction in which the failure to so qualify
would have a material adverse effect on its business, as now conducted
or as now proposed to be conducted, or properties. True and accurate
copies of the Company's Certificate of
* THE CONFIDENTIAL MATERIAL
2 CONTAINED HEREIN HAS BEEN
OMITTED AND HAS BEEN FILED
SEPARATELY WITH THE
COMMISSION
<PAGE>
Incorporation (the "Articles") and the Company's Bylaws, each as in
effect at the Initial Closing, are attached hereto as Exhibit C and
---------
Exhibit D, respectively.
---------
2.2. Capitalization; Voting Rights. The authorized capital
-----------------------------
stock of the Company, immediately prior to the Closing, will consist of
45,000,000 shares of Common Stock, par value $.002 per share,
22,289,863 shares of which are issued and outstanding and 9,211,000
shares of Preferred Stock, par value $.001 per share, none of which are
issued and outstanding. All issued and outstanding shares of the
Company's Common Stock (a) have been duly authorized and validly issued
(b) are fully paid and nonassessable, and (c) were issued in compliance
with all applicable state and federal laws concerning the issuance of
securities. The rights, preferences, privileges and restrictions of the
Shares are as stated in the Articles. Other than the 3,876,345 shares
reserved for issuance under the Company's Stock Option Plans, and
except as may be granted pursuant to the Affiliated Agreements (as
defined below), there are 2,144,236 shares of Common Stock reserved for
other purposes. Of such reserved shares of Common Stock, (i) 596,625
shares have been reserved pursuant to stock option agreements, and (ii)
1,547,611 have been reserved pursuant to warrant agreements. When
issued in compliance with the provisions of this Agreement and the
Articles, the Shares will be validly issued, fully paid and
nonassessable, and will be free of any liens or encumbrances; provided
however, that the Shares may be subject to restrictions on transfer
under state and/or federal securities laws as set forth herein or as
otherwise required by such laws at the time a transfer is proposed.
2.3. Subsidiaries. The Company does not presently own or
------------
control, directly or indirectly, any interest in any other corporation,
association or other business entity. The Company is not a participant
in any joint venture, partnership or similar arrangement.
2.4. Authorization. All corporate action on the part of the
-------------
Company and its officers, directors and shareholders necessary for the
authorization, execution and delivery of this Agreement, the
Registration Rights Agreement and the Option Agreement (together with
the Registration Rights Agreement, the "Affiliated Agreements"), the
performance of all obligations of the Company hereunder and thereunder
and under the Articles, and the authorization, issuance (or reservation
for issuance), sale and delivery of the Shares being sold hereunder,
has been taken or will be taken prior to the Closing, and this
Agreement and the Affiliated Agreements constitute valid and legally
binding obligations of the Company, enforceable in accordance with
their respective terms, subject to: (i) judicial principles limiting
the availability of specific performance, injunctive relief and other
equitable remedies; (ii) bankruptcy, insolvency, reorganization,
moratorium or other similar laws now or hereafter in effect generally
relating to or affecting creditors' rights; and (iii) limitations on
the enforceability of the indemnification provisions of the
Registration Rights Agreement.
2.5 Valid Issuance of Common Stock. The Shares that are being
------------------------------
purchased by the Investor hereunder, when issued, sold and delivered in
accordance with the terms of this Agreement for the consideration
expressed herein, will be duly and validly issued (including, without
limitation, issued in compliance with applicable state and federal
securities laws), fully paid and nonassessable, will have the rights,
preferences, privileges and instructions described in the Articles, and
will be free of restrictions on transfer other than restrictions on
transfer under this Agreement and the Registration Rights Agreement and
under applicable state and federal securities laws. Subject to
applicable restrictions on transfer, the issuance and delivery of the
Shares are not subject to any preemptive or other similar rights or any
liens or encumbrances except as specifically set forth in the Articles,
this Agreement and the Registration Rights Agreement.
3
<PAGE>
2.6. Governmental Consents. Based in part on the
---------------------
representations made by Investor in Section 3 of this Agreement, no
consent, approval, order or authorization of, or registration,
qualification, designation, declaration or filing with, any federal,
state or local governmental authority on the part of the Company is
required in connection with the offer, sale or issuance of the Shares,
or the consummation of any other transaction contemplated by this
Agreement or any of the Affiliated Agreements, except for (i) such
filings under applicable securities laws and (ii) such filings with the
Securities and Exchange Commission (the "Commission"), Nasdaq and
others pursuant to this Agreement and the Registration Rights
Agreement. The Company hereby agrees to make all such filings within
the prescribed periods. Based in part on the representations of the
Investor set forth in Section 3 below, the offer, sale and issuance of
the Shares in conformity with the terms of this Agreement are exempt
from the registration requirements of the Securities Act and from the
qualification requirements of the California Securities Law.
2.7. Litigation. There is no action, suit, proceeding or
----------
investigation pending or currently threatened before any court,
administrative agency or other governmental body against the Company
that questions the validity of this Agreement or the Affiliated
Agreements or the right of the Company to enter into any of them, or to
consummate the transactions contemplated hereby or thereby, or that
would result, either individually or in the aggregate, in any material
adverse change in the condition (financial or otherwise), business,
property, assets or liabilities of the Company or any change in the
current equity ownership of the Company. The foregoing includes,
without limitation, actions, suits, proceedings or investigations
pending or threatened (or any basis therefor known to the Company)
involving the prior employment of any of the Company's employees, their
use in connection with the Company's business of any intellectual
property, information or techniques allegedly proprietary to any of
their former employers, or their obligations under any agreements with
their former employers. The Company is not a party or subject to, and
none of its assets us bound by, the provisions of any order, writ,
injunction, judgment or decree of any court or government agency or
instrumentality.
2.8. Employees. The Company's relations with its employees are
---------
satisfactory. The Company has no collective bargaining agreements with
any of its employees. There is no labor union organizing activity
pending or, to the Company's knowledge, threatened with respect to the
Company. To the Company's knowledge, no employee of the Company, nor
any consultant with whom the Company has contracted, is in violation of
any term of any employment contract, proprietary information agreement
or any other agreement relating to the right of any such individual to
be employed by, or to contract with, the Company because of the nature
of the business to be conducted by the Company; and to the Company's
knowledge the continued employment by the Company of its present
employees, and the performance of the Company's contracts with its
independent contractors, will not result in any such violation. The
Company has not received any notice alleging that any such violation
has occurred. No employee of the Company has been granted the right to
continued employment by the Company or to any material compensation
following termination of employment with the Company. The Company is
not aware that any officer or key employee, or that any group of key
employees, intends to terminate his, her or their employment with the
Company, nor does the Company have a present intention to terminate the
employment of any officer, key employee or group of key employees. The
Company has complied in all material respects with the applicable
state, federal and foreign equal employment opportunity laws and with
other laws related to employment.
2.9. Patents and Trademarks. The Company has sufficient title
----------------------
and ownership of all patents, trademarks, service marks, trade names,
copyrights, trade secrets, information, proprietary
4
<PAGE>
rights and processes necessary for its business as presently conducted,
without any known infringement of the rights of others. The Company has
not received any communications alleging that the Company has violated
any patents, trademarks, service marks, trade names, copyrights or
trade secrets or other proprietary rights of any other person or entity
nor is the Company aware of any third party that us infringing or
violating any such rights of the Company. To the best knowledge of the
Company, none of the Company's employees is obligated under any
contract (including licenses, covenants or commitments of any nature)
or other agreement, or subject to any judgment, decree or order of any
court or administrative agency, that would interfere with the use of
his or her best efforts to promote the interests of the Company or that
would conflict in any manner with the Company's business. Neither the
execution nor delivery of this Agreement or any of the Affiliated
Agreements, nor the carrying on of the Company's business by the
employees of the Company, will conflict with or result in a breach of
the terms, conditions or provisions of, or constitute a default under,
any contract, covenant or instrument under which any of such employees
is now obligated. The Company does not and will not need to utilize any
inventions of any of its employees (or people it currently intends to
hire) made prior to their employment by the Company that have not
previously been fully and exclusively assigned to the Company without
restrictions, the presence of which would result in a material adverse
effect on the ability of the Company to carry on its business as
presently conducted or proposed to be conducted.
2.10. Confidential Information and Invention Assignment
-------------------------------------------------
Agreements. Each former and current employee, officer and consultant of
----------
the Company has executed an appropriate confidential information and
invention assignment agreement. No current employee, officer or
consultant of the Company has excluded works or inventions made prior
to his or her employment with the Company from his or her assignment of
inventions pursuant to such agreement.
2.11. Compliance with Other Instruments. The Company is not in
---------------------------------
violation or default of any provision of its Articles or Bylaws, each
as in effect on and as of the Closing. The Company is not in violation
or default of any material provision of any instrument, mortgage, deed
of trust, loan, contract, commitment, judgment, decree, order or
obligation to which it is a party or by which it or any of its
properties or assets are bound, which violation or default would
materially adversely affect the condition (financial or otherwise),
business, property, assets or liabilities of the Company or, to the
best of the Company's knowledge, of any provision of any federal, state
or local statute, rule or governmental regulation, which violation or
default would materially adversely affect the condition (financial or
otherwise), business, property, assets or liabilities of the Company.
The execution, delivery and performance of and compliance with this
Agreement and the Affiliated Agreements, and the issuance and sale of
the Shares, will not result in any such violation, be in conflict with
or constitute (with or without the passage of time or giving of notice)
a default under any such provision, require any consent or waiver under
any such provision (other than any consents or waivers that have been
obtained), or result in the creation of any mortgage, pledge, lien,
encumbrance or charge upon any of the properties or assets of the
Company pursuant to any such provision.
2.12 Ludwig Agreement. The Company has provided the Investor
----------------
with a full and complete (except for certain financial terms, which
have been redacted) copy of the License Agreement, dated as of December
20, 1996 (the "Ludwig Agreement"), by and between the Company and the
Ludwig Institute for Cancer Research, a Swiss not-for-profit
corporation ("Ludwig") which agreement is attached hereto as Exhibit E.
---------
The Ludwig Agreement constitutes the full and entire understanding
between the Company and Ludwig with respect to the subject matter of
the Ludwig Agreement. The Company is not in violation or default of any
provision of
5
<PAGE>
the Ludwig Agreement. The execution, delivery and performance of and
compliance with this Agreement and the Affiliated Agreements, and the
issuance and sale of the Shares, will not result in any such
violation, be in conflict with or constitute (with or without the
passage of time or giving of notice) a default under any such
provision, require any consent or waiver under any such provision or
result in the creation of any mortgage, pledge, lien encumbrance or
charge upon any of the properties or assets of the Company pursuant to
any such provision. The Company shall use its best efforts to maintain
the Ludwig Agreement in full force and effect through one hundred
twenty (120) days after the end of the Research Term (as defined in the
Option Agreement).
2.13 Permits. The Company has all material franchises,
-------
permits, licenses and any similar authority necessary for the conduct
of its business as now being conducted by it, the lack of which would
materially and adversely affect the business, properties, prospects or
financial condition of the Company, and the Company believes it can
obtain, without undue burden or expense, any similar authority for the
conduct of its business as planned to be conducted. The Company is not
in default under any of such franchises, permits, licenses or other
similar authority and neither the execution, delivery nor performance
of this Agreement and each of the Affiliated Agreements and the
consummation of the transactions contemplated hereby and thereby will
result in any suspension, revocation, impairment, forfeiture or
nonrenewal of any permit, license, authorization or approval applicable
to the Company, its business or operations or any of its assets or
properties.
2.14. Registration Rights. Except as provided in the
-------------------
Registration Rights Agreement, the Company has not granted or agreed to
grant any registration rights, including piggyback rights, to any
person or entity.
2.15. Title to Property and Assets. The Company has good and
----------------------------
marketable title to all of its properties and assets free and clear of
all mortgages, liens and encumbrances, except liens for current taxes
and assessments not yet due and possible minor liens and encumbrances
that do not, in any case, in the aggregate, materially detract from the
value of the property subject thereto or materially impair the
operations of the Company. With respect to the properties and assets it
leases, the Company is in compliance with such leases and holds a valid
leasehold interest free of all liens, claims or encumbrances, and to
the best knowledge of the Company, all other parties to the leases are
in compliance with all material terms of such leases. The Company's
properties and assets are in good condition and repair in all material
respects.
2.16. Brokers or Finders. The Company has not agreed to incur,
------------------
directly or indirectly, any liability for brokerage or finders' fees,
agents' commissions or other similar charges in connection with this
Agreement or any of the transactions contemplated hereby.
2.17. Financial Statements. The Company has delivered to the
--------------------
Investor its unaudited balance sheet as of September 30, 1998, its
unaudited statement of operations, stockholders' equity and cash flows
for the calendar period from January 1, 1998 through such date (the
Financial Statements"). The Financial Statements fairly and accurately
present the Company's financial position as of those dates and the
results of operations and changes in its financial position for such
periods then ended, and have been prepared in accordance with generally
accepted accounting principles ("GAAP") applied on a consistent basis,
subject to normal year-end adjustments, except that unaudited Financial
Statements may not contain all footnotes required by GAAP. There are no
debts, liabilities or claims against the Company that are not currently
reflected in the Financial Statements, contingent or otherwise, that
are or would be of a nature required to be reflected in a
6
<PAGE>
balance sheet prepared in accordance with GAAP. The Company has no
material liabilities other than those set forth in the Financial
Statements and Schedule of Exceptions. The Company is not a guarantor
or indemnitor of any indebtedness of any other person, firm or
corporation.
2.18. Absence of Changes. Except as specifically set forth in
------------------
this Agreement, since September 30, 1998: (a) the Company has not
entered into any transaction that was not in the ordinary course of
business; (b) there has been no material adverse change in the
condition (financial or otherwise) of the business, prospects,
property, assets or liabilities of the Company; (c) there has been no
damage to, destruction of or loss of physical property (whether or not
covered by insurance) materially and adversely affecting the assets,
financial condition, operating results, prospects, business or
operations of the Company; (d) the Company has not declared or paid any
dividend or made any distribution on its stock, or redeemed or
purchased or otherwise acquired any of its stock or incurred any
material tax liability; (e) the Company has not changed any
compensation arrangement or agreement with any of its key employees or
executive officers, or changed the rate of pay of its employees as a
group; (f) the Company has not received notice that there has been a
loss of a material customer of the Company; (g) the Company has not
changed or amended any contract by which the Company or any of its
assets are bound or subject that would have a material adverse effect
on the Company; (h) there has been no resignation or termination of
employment of any officer or key employee of the Company, and the
Company does not know of any impending resignation or termination of
employment of any such officer or key employee that if consummated
would have a material adverse effect on the Company; (i) there has been
no labor dispute involving the Company or any of its employees and, to
the knowledge of the Company, none is pending or threatened, (j) there
has been no material and adverse change in the contingent obligation of
the Company (nor in any material contingent obligation of the Company
regarding any director, stockholder or key employee or officer of the
Company) by way of guaranty, endorsement, indemnity, warranty or
otherwise; (k) there have been no loans or guarantees made by the
Company to any of its employees, officers or directors other than
travel advances and other advances made in the ordinary course of
business; (1) there has been no waiver by the Company of a valuable
right or of a debt owing to the Company that would have a material
adverse effect on the Company; (m) there has not been any satisfaction
or discharge of any material lien, claim or encumbrance or any payment
of any material obligation by the Company except in the ordinary course
of business and that is not material to the assets, properties,
financial condition, operating results or business of the Company; (n)
the Company has not sold or transferred any patent, service mark, trade
name, copyright, trade secret or proprietary right necessary for its
business; and (o) there has been no other event or condition of any
character that would have a material adverse effect on the Company.
2.19. Related-Party Transactions. No employee, officer or
--------------------------
director of the Company or member of his or her immediate family is
indebted to the Company, nor is the Company indebted (or committed to
make loans or extend or guarantee credit) to any of them. To the best
of the Company's knowledge, none of such persons has any direct or
indirect ownership interest in any firm or corporation with which the
Company is affiliated or with which the Company has a business
relationship, or any firm or corporation that competes with the
Company, except that employees, officers or directors of the Company
and members of their immediate families may own stock in publicly
traded companies that may compete with the Company. No member of the
immediate family of any officer or director of the Company is directly
or indirectly interested in any material contract with the Company.
7
<PAGE>
2.20. Environmental and Safety Laws. The Company, to the best
-----------------------------
of its knowledge, is not in violation of any applicable statute, law or
regulation relating to the environment or occupational health and
safety, and, based on the Company's business as currently conducted and
no the best of its knowledge, no material expenditures are or will be
required in order to comply with any such existing statute, law or
regulation.
2.21. Manufacturing and Marketing Rights. The Company has not
----------------------------------
granted rights to manufacture, produce, assemble, license, market or
sell its products to any other person and is not bound by any agreement
that affects the Company's exclusive right no develop, manufacture,
assemble, distribute, market or sell its products.
2.22. Disclosure. The Company has fully provided the Investor
----------
with all the information that the Investor has requested for deciding
whether to purchase the Shares. No representation or warranty by the
Company in this Agreement or any statement or certificate furnished to
the Investor pursuant hereto or in connection with the transactions
contemplated hereby contains or will contain any untrue statement of a
material fact or omits or will omit to state a material fact necessary
to make the statements made therein, in the light of the circumstances
under which they were made, not misleading.
2.23. Insurance. The Company has in full force and effect fire
---------
and casualty insurance policies, with extended coverage, sufficient in
amount (subject to reasonable deductibles) to allow it to replace any
of its properties that might be damaged or destroyed. The Company has
in full force and effect products liability insurance in amounts
customary for companies similarly situated. To the best of the
Company's knowledge, there is no pending or threatened claim against
the Company for personal injury or property damage that would have a
material adverse effect on the business, assets, liabilities, financial
condition, operations or prospects of the Company.
2.24. Tax Returns. All federal, state and local tax returns, if
-----------
any, required to be filed by the Company have been timely filed, and
all federal, state and local taxes, if any, required to be paid with
respect to the periods covered by such returns have been paid.
3. Representations and Warranties of the Investor. The Investor
----------------------------------------------
hereby represents and warrants to the Company with the respect to the
transactions contemplated hereby that:
3.1. Investment. The Investor has been provided with copies of
----------
the Company's Annual Report on Form 10-K for the year ended December
31, 1997, and its Quarterly Reports on Form 10-Q for the quarters ended
March 31, 1998, June 30, 1998 and September 30, 1998 and as of the
Initial Closing has been given the financial and other information
requested by the Investor or deemed by the Investor to be material for
it to make an analysis and decision concerning the investment in the
Shares contemplated by this Agreement. The Investor has been provided
with an opportunity for a reasonable period of time prior to the
Initial Closing to ask questions of, and receive answers from, the
Company and its representatives concerning the Company and the
investment in the Shares. The Investor has not been furnished with any
oral information in connection with the offering of the Shares. The
Investor is acquiring the Shares for investment for its own account and
not with the view to, or for resale in connection with, any
distribution thereof. The Investor understands that the Shares have not
been registered under the Securities Act by reason of a specific
exemption from the registration provisions of the Securities Act that
depends upon, among other things, the bona fide nature of the
investment intent as expressed herein. The Investor further represents
that it does not have any contract, undertaking, agreement or
8
<PAGE>
arrangement with any person to sell, transfer or grant participation to
any third person with respect to any of the Shares. The Investor
understands and acknowledges that the offering of the Shares pursuant
to this Agreement will not be registered under the Securities Act
3.2 Rule 144. The Investor acknowledges than the Shares must be
--------
held indefinitely unless subsequently registered under the Securities
Act or an exemption from such registration is available. The Investor
is aware of the provisions of Rule 144 promulgated under the Securities
Act that permit limited resale of shares purchased in a private
placement subject to the satisfaction of certain conditions. The
Investor covenants that, in the absence of an effective registration
statement covering the shock in question, it will sell, transfer or
otherwise dispose of the Shares only in a manner consistent with its
representations and covenants set forth in this Section 3. In
connection therewith, the Investor acknowledges than the Company will
make a notation on its stock books regarding the restrictions on
transfers set forth in this Section 3 and will transfer securities on
the books of the Company only to the extent not inconsistent therewith.
3.3. Authorization. This Agreement, when executed and
-------------
delivered by the Investor, will constitute a valid and legally binding
obligation of the Investor, enforceable in accordance with its terms
subject to: (1) judicial principles respecting election of remedies or
limiting the availability, of specific performance, injunctive relief,
and other equitable remedies; (ii) bankruptcy, insolvency,
reorganization, moratorium or other similar laws now or hereafter in
effect generally relating to or affecting creditors' rights; and (iii)
limitations on the enforceability of the indemnification provisions of
the Registration Rights Agreement.
4. Conditions of the Investor's Obligations at Closings. On or
----------------------------------------------------
before the Initial Closing and/or each of the Subsequent Closings, as specified,
the obligations of the Investor under this Agreement are subject to the
fulfillment on or before such Closing of each of the following conditions:
4.1. Representations and Warranties. The representations and
------------------------------
warranties of the Company contained in Section 2 shall be true on and
as of each Closing with the same effect as though such representations
and warranties bad been made on and as of the date thereof.
4.2. Performance. The Company shall have performed and complied
-----------
with all agreements, obligations and conditions contained in this
Agreement than are required to be performed or complied with by in on
or before each Closing.
4.3. Consents, Permits and Waivers. On or before each Closing,
-----------------------------
the Company shall have obtained any and all consents, permits and
waivers necessary or appropriate for consummation of the transactions
contemplated by this Agreement and the Affiliated Agreements (except
for such as may be properly obtained subsequent to such Closing).
4.4. Compliance Certificate. The Chief Executive Officer of
----------------------
the Company shall deliver to the Investor at each Closing a certificate
stating that the conditions specified in Sections 4.1, 4.2 and 4.3 have
been fulfilled.
4.5. Blue Sky. On or before the Initial Closing, the Company
--------
shall have filed the documents required of Company to maintain
requisite blue sky clearance in (A) all jurisdictions in which any of
the Shares is originally sold and (B) all other states specified in
writing by Investor, provided as to clause (B), however, that Company
shall not be required to qualify to do business
9
<PAGE>
or consent to service of process in any state in which it is not now so
qualified or has not so consented.
4.6. Registration Rights Agreement. The Company and the
-----------------------------
Investor shall have entered into the Registration Rights Agreement in
substantially the form attached hereto as Exhibit F.
---------
4.7. Option Agreement. The Company and the Investor shall have
----------------
entered into the Option Agreement.
4.8. Opinion of Company Counsel. The Investor shall have
--------------------------
received from Morgan, Lewis & Bockius LLP, outside counsel to the
Company, an opinion, dated as of such Closing, in the form attached
hereto as Exhibit G.
---------
4.9. Proceedings and Documents. All corporate and other
-------------------------
proceedings in connection with the transactions contemplated in connection with
the Investor's purchase of the Shares and all documents incident thereto shall
be reasonably satisfactory in form and substance to the Investor and the
Investor's counsel, and they shall have received all such counterpart original
and certified or other copies of such documents as they may reasonably request.
4.10. Delivery of Stock Certificate. The Company shall have
-----------------------------
caused the delivery to the Investor of a stock certificate representing
the Investor's ownership of the Shares.
5. Conditions of the Company's Obligations at Closing. On or
--------------------------------------------------
before the Initial Closing or each of the Subsequent Closings, as specified, the
obligations of the Company to the Investor under this Agreement are subject to
the fulfillment on or before such Closing of each of the following conditions:
5.1. Representations and Warranties. The representations and
------------------------------
warranties of the Company contained in Section 2 shall be true on and
as of each Closing with the same effect as though such representations
and warranties had been made on and as of the date thereof. The
representations and warranties of the Investor contained in Section 3
shall be true on and as of each Closing with the same effect as though
such representations and warranties had been made on and as of the date
thereof.
5.2. Payment of Purchase Price. The Investor shall have
-------------------------
delivered the purchase price specified in Exhibit A against delivery of
---------
the Shares by the Company to such Investor.
5.3. Blue Sky. On or before the Initial Closing, the Company
--------
shall have filed the documents required of Company to maintain
requisite blue sky clearance in (A) all jurisdictions in which any of
the Shares is originally sold and (B) all other states specified in
writing by Investor, provided as to clause (B), however, that Company
shall not be required to qualify to do business or consent to service
of process in any state in which it is not now so qualified or has not
so consented.
5.4. Registration Rights Agreement. The Company and the
-----------------------------
Investor shall have entered into the Registration Rights Agreement in
substantially the form attached hereto as Exhibit F.
---------
5.5. Option Agreement. The Company and the Investor shall have
----------------
entered into the Option Agreement.
10
<PAGE>
6. Post-Closing Covenants
----------------------
6.1. Securities Laws Compliance. The Company shall make any filings
--------------------------
required by the federal securities laws or the securities or Blue Sky laws of
any applicable state.
7. Miscellaneous
-------------
7.1. Governing Law. This Agreement shall be governed in all respects by
-------------
the laws of the State of New York, as applied to agreements among New York
residents entered into and to be performed entirely within New York, without
regard to the choice of law provisions thereof.
7.2. Successors and Assigns. Except as otherwise provided herein, the
----------------------
provisions hereof shall inure to the benefit of, and be binding upon, the
successors, assigns, heirs, executors and administrators of the parties hereto.
7.3. Entire Agreement Amendment. This Agreement, the other documents
--------------------------
delivered pursuant hereto, the Registration Rights Agreement and the Option
Agreement constitute the full and entire understanding and agreement among the
parties with regard to the subjects hereof and thereof. Neither this Agreement
nor any term hereof may be amended, waived, discharged or terminated other than
by a written instrument signed by the party against whom enforcement of any such
amendment, waiver, discharge or termination is sought.
7.4. Notices, Etc. All notices and other communications required or
------------
permitted hereunder shall be in writing and shall be mailed by registered or
certified mail, postage prepaid, return receipt requested, or by telecopier or
otherwise delivered by hand or by messenger, addressed or telecopied as follows:
(i) if to the Investor, at the Investor's address or telecopier number set forth
on the first page hereof, or to telecopier number (650) 952-9881, or at such
other address or telecopier number as the Investor shall have furnished to the
Company in writing, in each case to the attention of the Corporate Secretary;
(ii) if to any other holder of any Shares, at such address or telecopier number
as such holder shall have furnished the Company in writing or, until any such
holder so furnishes an address or telecopier number to the Company, then to and
at the address or telecopier number of the last holder of such Shares who has so
furnished an address to the Company; or (iii) if to the Company, at its address
set forth on the first page of this Agreement, or to telecopier number
(610) 941-5399, or at such other address or telecopier number as the Company
shall have furnished to the Investor, in each case to the attention of the
Corporate Secretary. If notice is provided by mail, notice shall be deemed to he
given upon proper deposit with the United States mail or nationally recognized
overnight courier, or personally delivered, to an Investor at the address
provided above. If notice is provided by telecopier, notice shall be deemed to
be given upon confirmation by the telecopier machine of the receipt of such
notice at the telecopier number provided above
7.5. Delays or Omissions. No delay or omission to exercise any right,
-------------------
power or remedy accruing to the Investor or to the Company upon any breach or
default under this Agreement shall impair any such right, power or remedy, nor
shall it be construed to he a waiver of any such breach or default, or an
acquiescence therein, or of or in any similar breach or default thereafter
occurring; nor shall any waiver of any single breach or default be deemed a
waiver of any other breach or default theretofore or thereafter occurring. Any
waiver, permit, consent or approval of any kind or character on the part of the
Investor or the Company of any breach or default under this Agreement, or any
waiver on the part of the Investor or the Company of any
11
<PAGE>
provisions or conditions of this Agreement, must be in writing and shall be
effective only to the extent specifically set forth in such writing or as
provided in this Agreement. All remedies, either under this Agreement or by law
or otherwise, shall be cumulative and not alternative.
7.6. Severability of this Agreement. In the event that any provision of
------------------------------
this Agreement becomes or is declared by a court of competent jurisdiction to he
illegal, unenforceable or void, this Agreement shall continue in full force and
effect without said provision and the parties agree to replace such provision
with a valid and enforceable provision that will achieve, to the extent
possible, the economic, business and other purposes of such provisions; provided
that no such severability shall be effective against a party if it materially
and adversely changes the economic benefits of this Agreement to such party.
7.7. Table of Contents, Headings, Etc. The Table of Contents and the
--------------------------------
headings of the Sections of this Agreement, and the headings on the signature
pages of this Agreement categorizing the signatories hereto, have beep inserted
for convenience of reference only, are not to be considered a part hereof, and
shall in no way modify or restrict any of the terms and provisions hereof
7.8. Counterparts, Facsimile. This Agreement may be executed in any
-----------------------
number of counterparts and by facsimile, each of which may be executed by fewer
than all of parties hereto, each of which shall be enforceable against the
parties actually executing such counterparts, and all of which together shall
constitute one instrument.
[signature page follows]
12
<PAGE>
IN WITNESS WHEREOF, the parties have executed this Agreement as of the
date first written above.
MAGAININ PHARMACEUTICALS INC.
BY: /s/ M. Dougherty
-------------------------------
Name: Michael R. Dougherty
Title: President and Chief Executive Officer
GENENTECH, INC.
BY: /s/ W. D. Young
-------------------------------
Name: William D Young
Title: Chief Operating Officer
13
<PAGE>
EXHIBIT A
---------
SCHEDULE OF CLOSINGS
<TABLE>
<CAPTION>
- -------------------------------------------------------------------------------------------------------
Date Initial Closing or Per Share Shares of Aggregate
of Closing a Subsequent Purchase Price Common Stock Consideration
Closing
- -------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C>
December 30, 1998 Initial $3.223 620,540 $2,000,000.42
- -------------------------------------------------------------------------------------------------------
Subsequent
- -------------------------------------------------------------------------------------------------------
Subsequent
- -------------------------------------------------------------------------------------------------------
Subsequent
- -------------------------------------------------------------------------------------------------------
</TABLE>
The number of spaces provided for by this chart shall not be construed to
determine such number of Subsequent Closings, if any.
A-1
<PAGE>
EXHIBIT B
---------
SCHEDULE OF EXCEPTIONS
There are no exceptions to the representations and warranties set forth
in Section 2 of the Agreement.
B-1
<PAGE>
EXHIBIT C
---------
CERTIFICATE OF INCORPORATION
* The Certificate of Incorporation has been previously filed as an Exhibit to
the Annual Report on Form 10-K for the year ended June 30, 1992 filed with
the Securities and Exchange Commission on September 24, 1992. The
Certificate of Amendment of Restated Certificate of Incorporation was
previously filed as an Exhibit to the Annual Report on Form 10-K for the
year ended December 31, 1996 filed with the Securities and Exchange
Commission on March 31, 1997.
C-1
<PAGE>
EXHIBIT D
---------
BYLAWS
* The By-laws have been previously filed as an Exhibit to Registration
Statement (No. 33-43579) on Form 5-1 filed with the Securities and Exchange
Commission on October 24, 1991 .
D-l
<PAGE>
EXHIBIT E
---------
LUDWIG AGREEMENT
***
* THE CONFIDENTIAL MATERIAL CONTAINED
HEREIN HAS BEEN OMITTED AND HAS BEEN
FILED SEPARATELY WITH THE COMMISSION
E-1
<PAGE>
EXHIBIT F
---------
FORM OF REGISTRATION RIGHTS AGREEMENT
F-I
<PAGE>
EXECUTION COPY
--------------
MAGAININ PHARMACEUTICALS INC.
REGISTRATION RIGHTS AGREEMENT
December 30, 1998
THIS REGISTRATION RIGHTS AGREEMENT (this "Agreement") is made and
entered into as of the date first written above by and between MAGAININ
PHARMACEUTICALS INC., a Delaware corporation having its principal executive
offices at 5110 Campus Drive, Plymouth Meeting, Pennsylvania 19462 (the
"Company") and GENENTECH, INC., a Delaware corporation having its principal
executive offices at 1 DNA Way, South San Francisco, California 94080 (the
"Investor").
RECITALS
WHEREAS, the Company and the Investor have entered into that certain
Common Stock Purchase Agreement, dated as of the date hereof (the "Stock
Purchase Agreement), and than certain Collaborative Research and Option
Agreement, dated as of the date hereof (the "Option Agreement" and, together
with the Stock Purchase Agreement, the "Affiliated Agreements"); and
WHEREAS, the full execution and delivery of this Agreement is a
condition to the closing of the purchase and sale of the Common Stock as
contemplated by the Stock Purchase Agreement; and
WHEREAS, in order to further induce the Investor to enter into, and to
make the investment in the Company contemplated by, the Affiliated Agreements,
the Company agreed to enter into this Agreement substantially in the form
attached to the Stock Purchase Agreement, and
WHEREAS, the Company and the Investor have agreed to the final terms of
this Agreement as set forth herein,
Now, THEREFORE, in consideration of the mutual promises and covenants
set forth herein,
THE PARTIES HERETO AGREE AS FOLLOWS:
1. RESTRICTIONS ON TRANSFERABILITY OF SECURITIES; REGISTRATION RIGHTS.
1.1 Certain Definitions As used in this Agreement, the following
terms shall have the meanings set forth below:
(a) "Closing" shall mean the Initial Closing or any Subsequent
Closing, as applicable.
(b) "Commission" shall mean the Securities and Exchange
Commission or any other federal agency at the time administering the Securities
Act.
(c) "Exchange Act" shall mean the Securities Exchange Act of
1934, as amended, or any similar successor federal statute and the rules and
regulations thereunder, all as the same shall be in effect from time to time
1
<PAGE>
(d) "Holder" shall mean the Investor and any holder of
Registrable Securities to whom the registration rights conferred by this
Agreement have been transferred in compliance with Section 1.2 hereof.
(e) "Initial Closing" shall have the meaning ascribed to it in
the Stock Purchase Agreement.
(f) "Other Investors" shall mean persons other than Holders
who, by virtue of agreements with the Company, are entitled to include their
securities in any registrations hereunder.
(g) "Registrable Securities" shall mean (i) the Shares, (ii)
any additional shares that may be issued by the Company to the Investor as
contemplated by Section 1.3 of the Stock Purchase Agreement, and (iii) any
Common Stock issued as a dividend or other distribution with respect to or in
exchange for or in replacement of the Shares or such additional shares,
provided, however, that Registrable Securities shall not include any shares of
Common Stock that have previously been registered or than have been sold to the
public either pursuant to a registration statement or Rule 144, that have been
sold in a private transaction in which the transferor's rights under this
Agreement are not assigned, or that are no longer registrable pursuant to
Section 1.11 hereof.
(h) The terms "register," "register" and "registration" shall
refer to a registration effected by preparation and filing a registration
statement in compliance with the Securities Act and applicable rules and
regulations thereunder, and the declaration or ordering of the effectiveness of
such registration statement.
(i) "Registration Expenses" shall mean all expenses incurred
in effecting any registration pursuant to this Agreement, including, without
limitation, all registration, qualification and filing fees, printing expenses,
escrow fees, all fees and disbursements of counsel for the Company, blue sky
fees and expenses, and expenses of any regular or special audits incident to or
required by any such registration, but shall not include the compensation of
regular employees of the Company, which shall be paid in any event by the
Company, and Selling Expenses.
(j) "Restricted Securities" shall mean any Registrable
Securities required to bear the legend set forth in Section 1.2(b) hereof.
(k) "Rule 144" shall mean Rule 144 as promulgated by the
Commission under the Securities Act, as such Rule may be amended from time to
time, or any similar successor rule that may be promulgated by the Commission.
(l) "Rule 145" shall mean Rule 145 as promulgated by the
Commission under the Securities Act, as such Rule may be amended from time to
time, or any similar successor rule that may be promulgated by the Commission.
(m) "Securities Act" shall mean the Securities Act of 1933, as
amended, or any similar successor federal statute and the rules and regulations
thereunder, all as the same shall be in effect from time to time.
(n) "Selling Expenses" shall mean all underwriting discounts,
selling commissions and stock transfer taxes applicable to the sale of
Registrable Securities and the cost of any accountants, counsel or other experts
retained in connection with such sale by the Holder or Holders or, with their
prior written consent, on behalf of the Holder or Holders.
2
<PAGE>
(o) "Shares" shall mean the Company's Common Stock issued and
sold to the Investor pursuant to Section 1.2 of the Stock Purchase Agreement.
(p) "Subsequent Closing" shall have the meaning ascribed to it
in the Stock Purchase Agreement.
1.2 Restrictions on Transfer
(a) Each Holder agrees not to make any disposition of all or
any portion of the Registrable Securities unless and until the transferee has
agreed in writing for the benefit of the Company to be bound by this Section
1.2, which is intended to ensure compliance with the provisions of the
Securities Act, provided and to the extent this Section 1.2 is then applicable
under the Securities Act to such disposition, and unless and until:
(i) There is then in effect a registration
statement under the Securities Act covering such proposed disposition
and such disposition is made in accordance with such registration
statement; or
(ii) (A) Such Holder shall have notified the Company
of the proposed disposition and shall have furnished the Company with
a statement of the circumstances surrounding the proposed disposition,
and (B) if reasonably requested by the Company, such Holder shall have
furnished the Company with (l) an opinion of counsel, reasonably
satisfactory to the Company, that such disposition will not require
registration of such shares under the Securities Act, (2) a "no
action" letter from the Commission to the effect that the transfer of
such securities without registration will not result in a
recommendation by the staff of the Commission that action be taken
with respect thereto; or (3) any other evidence reasonably
satisfactory to counsel to the Company. It is agreed that the Company
will not require opinions of counsel, "no action" letters or any other
such evidence; in any transaction in which a Holder that is a
corporation distributes Restricted Securities after six months after
the purchase thereof solely to its majority owned subsidiaries or
affiliates for no consideration; or in any transaction in which a
Holder that is a partnership distributes Restricted Securities after
six months after the purchase thereof solely to partners thereof for
no consideration; provided, however, that each transferee agrees in
writing to be subject to the terms of this Section 1.2.
(iii) Notwithstanding the provisions of paragraphs
(i) and (ii) above, no such registration statement or opinion of
counsel shall be necessary for a transfer by a Holder that is (A) a
partnership to its partners or retired partners in accordance with
partnership interests, (B) a corporation to its shareholders in
accordance with their interest in the corporation, (C) a limited
liability company to its members or former members in accordance with
their interest in the limited liability company, or (D) to the
Holder's family member or trust for the benefit of an individual
Holder, provided the transferee will be subject to the terms of this
Section 1.2 to the same extent as if such transferee were an original
Holder hereunder.
(b) Each certificate representing Registrable Securities shall
(unless otherwise permitted by the provisions of this Agreement) be stamped or
otherwise imprinted with a legend substantially similar to the following (in
addition to any legend required under applicable state securities laws):
"THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ACQUIRED
FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), AND
MAY NOT BE SOLD, TRANSFERRED, ASSIGNED, PLEDGED OR
HYPOTHECATED
3
<PAGE>
UNLESS AND UNTIL REGISTERED UNDER THE SECURITIES ACT OR AN
OPINION OF COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO
MAGAININ PHARMACEUTICALS INC. (THE "COMPANY") THAT SUCH
REGISTRATION IS NOT REQUIRED."
"SUCH SHARES ARE SUBJECT TO RESTRICTIONS ON SALE, ASSIGNMENT
OR TRANSFER PURSUANT TO THE TERMS OF A REGISTRATION RIGHTS
AGREEMENT BETWEEN THE COMPANY AND THE STOCKHOLDER, A COPY OF
WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY, AND MAY
NOT BE SOLD, TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED
OTHER THAN IN COMPLIANCE WITH SUCH REGISTRATION RIGHTS
AGREEMENT."
(c) The Company shall promptly reissue unlegended certificates
at the request of any Holder thereof if the Holder shall have obtained an
opinion of counsel at such Holder's expense (which counsel may be counsel to the
Company) reasonably acceptable to the Company to the effect that the securities
represented thereby may lawfully be disposed of without registration,
qualification or legend.
(d) Any legend endorsed on an instrument pursuant to
applicable federal or state securities laws, and the stop-transfer instructions
with respect to such securities, shall be removed promptly upon the request of
any Holder thereof if the Holder shall have obtained an opinion of counsel at
such Holder's expense (which counsel may be counsel to the Company) reasonably
acceptable to the Company to the effect that such legend is, or instructions
are, no longer required.
1.3 Shelf Registration.
(a) Registration Statement. The Company shall, as soon as
----------------------
practicable, prepare and file with the Commission a Registration Statement on
Form S-3 (the "Registration Statement") to effect the registration under the
Securities Act of the Shares sold pursuant to the Stock Purchase Agreement in
connection with the disposition of all of the Shares by the Holders, from time
to time in the open market, in one or more transactions (which may involve block
transactions), in negotiated, underwritten, or other transactions or through a
combination of such methods of sale, at market prices prevailing at the time of
such sale, at prices relating to such prevailing market prices or at negotiated
prices, and shall use its best efforts to cause the Registration Statement to
become effective as soon as practicable thereafter, provided, however, that in
no event shall the Company be required in connection with this covenant to file
its Annual Report on Form 10-K prior to March 1, 1999. If such disposition is
pursuant to an underwritten offering, Company shall enter into an underwriting
agreement in form reasonably necessary to effect the offer and sale of Common
Stock in connection with any underwritten offering pursuant to this Section 1.3,
provided such underwriting agreement contains customary underwriting provisions.
(b) Additional Shares. The Company shall promptly prepare and
-----------------
file with the Commission one or more amendments to the Registration Statement
and the prospectus used in connection therewith to register for resale all of
the Registrable Securities.
(c) Amendments and Supplements. The Company shall promptly
--------------------------
prepare and file with the Commission such amendments and supplements to the
Registration Statement and the prospectus used in connection therewith as may be
necessary to keep the Registration Statement effective until all of the
Registrable Securities have been sold pursuant thereto or until the earlier of
(i) such time as all such Registrable Securities have been disposed of in
accordance with the intended methods of disposition by the Holders set forth in
such Registration Statement, and (ii) such date on which each Holder may dispose
4
<PAGE>
of all of the Registrable Securities held by it in one transaction in the open
market pursuant to Rule 144(k) under the Securities Act.
(d) Documents. The Company shall promptly furnish to each
---------
Holder with respect to the Registrable Securities registered under the
Registration Statement such number of copies of prospectuses and preliminary
prospectuses in conformity with the requirements of the Securities Act and such
other documents as the Holder may reasonably request, in order to facilitate the
public sale or other disposition of all or any of the Registrable Securities by
the Holder.
(e) Blue Sky. The Company shall promptly file documents
--------
required of the Company for normal blue sky clearance for the disposition by the
Holders of the Registrable Securities and in each state of the United States,
provided, however, that the Company shall not be required to qualify to do
business or consent to service of process in any jurisdiction in which it is not
not so qualified or has not so consented.
(f) Stop Orders. The Company shall promptly inform the Holders
-----------
when any stop order has been issued with respect to the Registration Statement
and use its best efforts to promptly cause such stop order to be withdrawn, and
in any event shall, within 45 days of the issuance of such stop order, amend the
Registration Statement in a manner reasonably expected to obtain the withdrawal
of the stop order or file an additional Registration Statement covering all of
the Registrable Securities and use its best efforts to cause such Registration
Statement to become effective as soon as practicable thereafter. In the event
that the Company files such subsequent Registration Statement pursuant hereto,
all of the provisions of this Section 1 shall apply with respect to such
Registration Statement.
(g) Expenses. The Company shall bear all Registration Expenses
--------
and the Holders shall bear all Selling Expenses.
(h) Notification. The Company shall notify each seller of
------------
Registrable Securities covered by such registration statement at any time when a
prospectus relating thereto is required to be delivered under the Securities Act
of the happening of any event as a result of which the prospectus included in
such registration statement, as then in effect, includes an untrue statement of
a material fact or omits to state a material fact required to be stated therein
or necessary to make the statements therein not misleading in the light of the
circumstances then existing, and at the request of any such seller, prepare and
furnish to such seller a reasonable number of copies of a supplement to or an
amendment of such prospectus as may be necessary so that, as thereafter
delivered to the purchasers of such shares, such prospectus shall not include an
untrue statement of a material fact or omit to state a material fact required to
be stated therein or necessary to make the statements therein not misleading or
incomplete in the light of the circumstances then existing.
(i) Listing. The Company shall cause all such Registrable
-------
Securities registered pursuant to this Agreement to be listed on each securities
exchange on which similar securities issued by the Company are then listed.
(j) CUSIP Number. The Company shall provide a transfer agent
------------
and registrar for all Registrable Securities registered pursuant to such
registration statement and a CUSIP number for all such Registrable Securities,
in each case not later than the effective date of such registration.
(k) Applicable Rules and Regulations. The Company shall
--------------------------------
otherwise use its best efforts to comply with all applicable rules and
regulations of the Commission.
5
<PAGE>
1.4 Indemnification.
(a) The Company shall indemnity each Holder, each of its
directors, officers, partners, legal counsel and accountants, and each person
controlling such Holder within the meaning of Section 15 of the Securities Act,
with respect to which registration, qualification or compliance has been
effected pursuant to this Section 1, and each underwriter, if any, and each
person who controls any underwriter within the meaning of Section 15 of the
Securities Act, against all expenses, claims, losses, damages and liabilities
(or actions, proceedings or settlements of litigation, commenced or threatened,
in respect thereof) arising out of or based on any untrue statement (or alleged
untrue statement) of a material fact contained in any prospectus, offering
circular or other document (including any related registration statement,
notification or the like) incident to any such registration, qualification or
compliance, or based on any omission (or alleged omission) to state therein a
material fact required to be stated therein or necessary to make the statements
therein, in light of the circumstances in which they were made, not misleading,
or any violation by the Company of the Securities Act or any rule or regulation
thereunder applicable to the Company and relating to action or inaction required
of the Company in connection with any such registration, qualification or
compliance, and will reimburse each such Holder, each of its officers,
directors, partners, legal counsel and accountants, and each person controlling
such Holder, each such underwriter, and each person who controls any such
underwriter, for any legal and any other expenses reasonably incurred in
connection with investigating, preparing and defending or settling any such
claim, loss, damage or liability (or action or proceeding in respect thereof),
provided that the Company will not be liable in any such case to the extent that
any such claim, loss, damage, liability or expense arises out of or is based on
any untrue statement or omission based upon written information furnished to the
Company by such Holder or underwriter and stated to be specifically for use
therein. It is agreed that the indemnity agreement contained in this Section
1.4(a) shall not apply to amounts paid in settlement of any such claim, loss,
damage or liability (or action or proceeding in respect thereof) if such
settlement is effected without the consent of the Company (which consent has not
been unreasonably withheld).
(b) Each Holder shall, if Registrable Securities held by such
Holder are included in the securities as to which such registration,
qualification or compliance is being effected, indemnify the Company, each of
its directors, officers, partners, legal counsel and accountants, and each
underwriter, if any, of the Company's securities covered by such a registration
statement, each person who controls the Company or such underwriter within the
meaning of Section 15 of the Securities Act, each other such Holder, and each
such Holder's directors, officers and partners, and each person controlling such
Holder, against all expenses, claims, losses, damages and liabilities (or
actions, proceedings or settlements of litigation, commenced or threatened, in
respect thereof) arising out of or based on any untrue statement (or alleged
untrue statement) of a material fact contained in any such registration
statement, prospectus, offering circular or other document, or any omission (or
alleged omission) to state therein a material fact required to be stated therein
or necessary to make the statements therein, in light of the circumstances in
which they were made, not misleading, and will reimburse the Company and such
Holders, directors, officers, partners, legal counsel and accountants,
underwriters or control persons for any legal or any other expenses reasonably
incurred in connection with investigating, preparing and defending or settling
any such claim, loss, damage or liability (or action or proceeding in respect
thereof), in each case to the extent, but only to the extent, that such untrue
statement (or alleged untrue statement) or omission (or alleged omission) is
made in such registration statement, prospectus, offering circular or other
document in reliance upon and in conformity with written information furnished
to the Company by such Holder and stated to be specifically for use therein;
provided, however, that the obligations of such Holder hereunder shall not apply
to amounts paid in settlement of any such expenses, claims, losses, damages or
liabilities (or actions or proceedings in respect thereof) if such settlement is
effected without the consent of such Holder (which consent shall not be
unreasonably withheld); and provided further that in no event
6
<PAGE>
shall any indemnity under this Section 1.4(b) exceed the gross proceeds from the
offering received by such Holder.
(c) Each party entitled to indemnification under this Section
1.4 (the "Indemnified Party") shall give notice to the party required to provide
indemnification (the "Indemnifying Party") promptly after such Indemnified Party
has actual knowledge of any claim as to which indemnity may be sought, and shall
permit the Indemnifying Party to assume the defense of such claim or any
litigation resulting therefrom, provided, however, that counsel for the
Indemnifying Party, who shall conduct the defense of such claim or any
litigation resulting therefrom, shall be approved by the Indemnified Party
(whose approval shall not unreasonably be withheld), and the Indemnified Party
may participate in such defense at such party's expense, and provided further
that an Indemnified Party (together with all other Indemnified Parties that may
be represented without conflict by one counsel) shall have the right to retain
one separate counsel, with the fees and expenses to be paid by the Indemnifying
Party, if representation of such Indemnified Party by the counsel retained by
the Indemnifying Party would be inappropriate due to actual or potential
differing interests between such Indemnified Party and any other party
represented by such counsel in such proceeding, and provided further that the
failure of any Indemnified Party to give notice as provided herein shall not
relieve the Indemnifying Party of its obligations under this Section 1.4, to the
extent such failure is not materially prejudicial to an Indemnifying Party's
ability to defend such action. No Indemnifying Party, in the defense of any such
claim or litigation, shall, except with the consent of each Indemnified Party,
consent to entry of any judgment or enter into any settlement that does not
include as an unconditional term thereof the giving by the claimant or plaintiff
to such Indemnified Party of a release from all liability in respect to such
claim or litigation. Each Indemnified Party shall furnish such information
regarding itself or the claim in question as an Indemnifying Party may
reasonably request in writing and as shall be reasonably required in connection
with defense of such claim and litigation resulting therefrom.
(d) If the indemnification provided for in this Section 1.4 is
held by a court of competent jurisdiction to be unavailable to an Indemnified
Party with respect to any expense, claim, loss, damage or liability referred to
herein, then the Indemnifying Party, in lieu of indemnifying such Indemnified
Party hereunder, shall contribute to the amount paid or payable by such
Indemnified Party as a result of such expense, claim, loss, damage or liability
in such proportion as is appropriate to reflect the relative fault of the
Indemnifying Party on the one hand and of the Indemnified Party on the other in
connection with the statements or omissions that resulted in such expense,
claim, loss, damage or liability as well as any other relevant equitable
considerations. The relative fault of the Indemnifying Party and of the
Indemnified Party shall be determined by reference to, among other things,
whether the untrue or alleged untrue statement of a material fact or the
omission or alleged omission to state a material fact that resulted in such
expense, claim, loss, damage or liability relates to information supplied by the
Indemnifying Party or by the Indemnified Party and the parties' relative intent,
knowledge, access to information and opportunity to correct or prevent such
statement or omission; provided that in no event shall any indemnity
contribution by a Holder under this Section 1.4(d) exceed the gross proceeds
from the offering received by such Holder.
(e) The obligations of the Company and Holders under this
Section 1.4 shall survive completion of any offering of Registrable Securities
in a registration statement and the termination of this Agreement. No
Indemnifying Party, in the defense of any action or proceeding with respect to
any such claim, loss, damage or liability, shall, except with the consent of
each Indemnified Party, consent to entry of any judgment or enter into any
settlement that does not include as an unconditional term thereof the giving by
the claimant or plaintiff to such Indemnified Party of a release from all
liability in respect to such claim or litigation.
7
<PAGE>
(f) Notwithstanding the foregoing, to the extent that the
provisions on indemnification and contribution contained in the underwriting
agreement entered into in connection with the underwritten public offering are
in conflict with the foregoing provisions, the provisions in the underwriting
agreement shall control; provided, however, that such provisions shall not
materially limit the Company's indemnification obligations provided hereby.
1.5 Information by Holder. Each Holder of Registrable Securities
shall furnish to the Company such information regarding such Holder and the
distribution proposed by such Holder as the Company may reasonably request in
writing and as shall be reasonably required in connection with any registration,
qualification or compliance referred to in this Section 1.
1.6 Rule 144 Reporting. With a view to making available the
benefits of certain rules and regulations of the Commission that may permit the
sale of the Restricted Securities to the public without registration, the
Company agrees to use its best efforts to:
(a) Make and keep public information regarding the Company
available, as those terms are understood and defined in Rule 144 under the
Securities Act, at all times (the Company being currently subject to the
reporting requirements of the Securities Act and the exchange Act);
(b) File with the Commission in a timely manner all reports
and other documents required of the Company under the Securities Act and the
Exchange Act.
(c) So long as a Holder owns any Restricted Securities,
furnish to the Holder forthwith upon its request, (i) a written certification by
the Company, signed by its Chief Executive Officer, that the Company is in
compliance with the reporting requirements of Rule 144, and of the Securities
Act and the Exchange Act, (ii) a copy of the most recent annual or quarterly
report of the Company, and (iii) such other reports and documents so filed as a
Holder may reasonably request in availing itself of any rule or regulation of
the Commission allowing a Holder to sell any such securities without
registration.
1.7 Transfer or Assignment of Registration Rights. The rights to
cause the Company to register securities granted to a Holder by the Company
under this Section 1 may be transferred or assigned by a Holder only to a
transferee or assignee of Registrable Securities, provided that the Company is
given written notice at the time of or within a reasonable time after said
transfer or assignment, stating the name and address of the transferee or
assignee and identifying the securities with respect to which such registration
rights are being transferred or assigned, and, provided further, that the
transferee or assignee of such rights assumes in writing the obligations of such
Holder under this Section I.
1.8 Market Stand-Off Agreement. If requested by the Company and an
underwriter of Common Stock (or other securities) of the Company, a Holder shall
not sell or otherwise transfer or dispose of any Common Stock (or other
securities) of the Company held by the Holder (other than those included in the
registration) during such period of time not to exceed ninety (90) days
following the effective date of a registration statement of the Company filed
under the Securities Act, provided that.
(i) such agreement shall only apply to the first such
registration statement of the Company hereafter, including securities
to be sold on its behalf to the public in an underwritten offering;
8
<PAGE>
(ii) all officers and directors of the Company, and holders
of Common Stock issued by the Company directly to such holders in an
exempt private transaction, are bound by and have entered into similar
agreements; and
(iii) such agreement shall apply only once in any calendar
year.
The obligations described in this Section 18 shall not apply to a registration
relating solely to employee benefit plans on Form S-8 or any similar form that
may be promulgated in the future, or a registration relating solely to a
Commission Rule 145 transaction on Form S-4 or any similar form that may be
promulgated in the future. The Company may impose stop-transfer instructions
with respect to the shares of Common Stock (or other securities) subject to the
foregoing restriction until the end of said ninety (90) day period.
1.9 Delay of Registration. No Holder shall have any right to take any
action to restrain, enjoin or otherwise delay any registration as the result of
any controversy that might arise with respect to the interpretation or
implementation of this Section 1.
1.10 Termination of Registration Rights. The right of any Holder to
inclusion in any registration pursuant to Section 1.3 shall terminate on such
date as all shares of Registrable Securities held by such Holder may immediately
be sold under Rule 144 during any 90-day period.
2. COVENANTS OF THE COMPANY
The Company hereby covenants and agrees, so long as any Holder owns any
Registrable Security, as follows:
2.1 Basic Financial Information. If the Company should no longer be
subject to the reporting requirements of the Exchange Act, the Company shall
furnish the following reports to each Holder:
(a) As soon as practicable after the end of each fiscal year of
the Company, and in any event within the period thereafter when a filing on Form
10-K would be required, a consolidated balance sheet of the Company and its
subsidiaries, if any, as at the end of such fiscal year, and consolidated
statements of income and cash flows of the Company and its subsidiaries, if any,
for such year, prepared in accordance with generally accepted accounting
principles consistently applied and setting forth in each case in comparative
form the figures for the previous fiscal year, all in reasonable detail and
certified by independent public accountants of recognized national standing
selected by the Company.
(b) As soon as practicable after the end of each of the first,
second and third quarterly accounting periods in each fiscal year of the
Company, and in any event within the period thereafter when a filing on Form
10-Q would be required, a consolidated balance sheet of the Company and its
subsidiaries, if any, as of the end of each such quarterly period, and
consolidated statements of income and cash flows of the Company and its
subsidiaries, if any, for such period and for the current fiscal year to date,
prepared in accordance with generally accepted accounting principles
consistently applied and setting forth in comparative form the figures for the
corresponding periods of the previous fiscal year, subject to changes resulting
from normal year-end audit adjustments, all in reasonable detail and certified
as to the foregoing by the principal financial or accounting officer of the
Company, except that such financial statements need not contain the notes
required by generally accepted accounting principles.
9
<PAGE>
3. MISCELLANEOUS.
3.1 Governing Law. This Agreement shall be governed in all respects by
the laws of the State of New York, as applied to agreements among New York
residents entered into and to be performed entirely within New York, without
regard to the choice of law provisions thereof.
3.2 Successors and Assigns. Except as otherwise expressly provided
herein, the provisions hereof shall inure to the benefit of, and be binding
upon, the successors, assigns, heirs, executors and administrators of the
parties hereto.
3.3 Entire Agreement. This Agreement, together with each of the
Affiliated Agreements, constitutes the full and entire understanding and
agreement between the parties with regard to the subjects hereof and thereof.
3.4 Notices, etc. All notices and other communications required or
permitted hereunder shall be in writing and shall be mailed by registered or
certified mail, postage prepaid, return receipt requested, or by telecopier or
otherwise delivered by hand or by messenger, addressed or telecopied as follows;
(i) if to the Investor, at the Investor's address or telecopier number set forth
on the first page hereof, or to telecopier number (650) 952-9881, or at such
other address or telecopier number as the investor shall have furnished to the
Company in writing, in each case to the attention of the Corporate Secretary;
(ii) if to any other holder of any Shares, at such address or telecopier number
as such holder shall have furnished the Company in writing or, until any such
holder so furnishes an address or telecopier number to the Company, then to and
at the address or telecopier number of the last holder of such Shares who has so
furnished an address to the Company; or (iii) if to the Company, at its address
set forth on the first page of this Agreement, or to telecopier number (610)
941-5399, or at such other address or telecopier number as the Company shall
have furnished to the Investor, in each case to the attention of the Corporate
Secretary. If notice is provided by mail, notice shall be deemed to be given
upon proper deposit with the United States mail or nationally recognized
overnight courier, or personally delivered, to an Investor at the address
provided above. If notice is provided by telecopier, notice shall be deemed to
be given upon confirmation by the telecopier machine of the receipt of such
notice at the telecopier number provided above.
3.5 Delays or Omissions. No delay or omission to exercise any right,
power or remedy accruing to any Holder, upon any breach or default of the
Company under this Agreement shall impair any such right, power or remedy of
such Holder nor shall it be construed to be a waiver of any such breach or
default, or an acquiescence therein, or of or in any similar breach or default
thereafter occurring; nor shall any waiver of any single breach or default be
deemed a waiver of any other breach or default therefore or thereafter
occurring. Any waiver, permit, consent or approval of any kind or character on
the part of any Holder of any breach, or default under this Agreement or any
waiver on the part of any Holder of any provisions or conditions of this
Agreement must be made in writing and shall be effective only to the extent
specifically set forth in such writing. All remedies, either under this
Agreement or by law or otherwise afforded to any Holder, shall be cumulative and
not alternative.
3.6 Rights. Unless otherwise expressly provided herein, a Holder's
rights hereunder are several rights, not rights jointly held with any of the
other Holders, if any.
3.7 Severability of this Agreement. In the event that any provision of
this Agreement becomes or is declared by a court of competent jurisdiction to be
illegal, unenforceable or void, this Agreement shall continue in full force and
effect without said provision and the parties agree to replace such provision
with a valid and enforceable provision that will achieve, to the extent
possible, the
10
<PAGE>
economic, business and other purposes of such provisions, provided that no such
severability shall be effective against a party if it materially and adversely
changes the economic benefits of this Agreement to such party.
3.8 Table of Contents, Headings, Etc. The Table of Contents and the
headings of the Sections of this Agreement have been inserted for convenience of
reference only, are not to be considered a part hereof, and shall in no way
modify or restrict any of the terms and provisions hereof.
3.9 Counterparts; Facsimile. This Agreement may be executed in any
number of counterparts and by facsimile, each of which shall be enforceable
against the party or parties actually executing such counterparts, and all of
which together shall constitute one instrument.
[signature page follows]
11
<PAGE>
IN WITNESS WHEREOF, the parties hereto have executed this Registration
Rights Agreement effective as of the date first above written.
MAGAININ PHARMACEUTICALS INC.
BY /s/ Michael R. Dougherty
---------------------------
Name: Michael R. Dougherty
Title: President and Chief Executive Officer
GENENTECH, INC
BY
---------------------------
Name:
Title:
12
<PAGE>
IN WITNESS WHEREOF, the parties hereto have executed this Registration
Rights Agreement effective as of the date first above written
MAGAININ PHARMACEUTICALS INC
BY:
----------------------------------
Name:
Title:
GENENTECH, INC
BY: /s/ William D. Young
----------------------------------
Name: William D. Young
Title: Chief Operating Officer
<PAGE>
EXHIBIT G
---------
FORM OF OPINION OF COMPANY COUNSEL
G-l
<PAGE>
[LETTERHEAD OF MORGAN, LEWIS & BOCKIUS LLP APPEARS HERE]
December 30, 1998
Genentech, Inc.
One DNA Way
South San Francisco, CA 94080
Re: Magainin Pharmaceuticals Inc.
----------------------------
Ladies and Gentlemen:
We have acted as counsel to Magainin Pharmaceuticals Inc., a Delaware
corporation (the "Company"), in connection with the issuance by the Company of
an aggregate of 620,540 shares (the "Shares") of the Company's common stock,
$.002 par value per share (the "Common Stock"), pursuant to a Stock Purchase
Agreement (the "Agreement"), dated as of December 30, 1998, between the Company
and Genentech, Inc. (the "Investor"). All capitalized terms used herein without
definition are used herein with the respective meanings ascribed to them in the
Agreement. This opinion is being delivered to you pursuant to Section 4.8 of the
Agreement.
In rendering this opinion, we have participated in the preparation of the
documents contemplated by the offering. We have examined executed counterparts
or copies certified or otherwise identified to our satisfaction of the Agreement
and the Affiliated Agreements. As to various questions of fact material to our
opinion, we have relied, without independent investigation, upon the
representations of the parties thereto set forth in the Agreement and the
Affiliated Agreements, and upon such certificates of officers and
representatives of such parties as we have deemed relevant, as well as
certificates of public officials.
We have also assumed the genuineness of all signatures, the authenticity of all
documents submitted to us as originals and the conformity with originals of all
documents submitted to us as copies. We have also assumed with respect to each
party other than the Company that the Agreement and the Affiliated Agreements
have been duly authorized, executed and delivered by such party and that each
party has full power and authority to execute, deliver and perform the Agreement
and the Affiliated Agreements to which it is a party.
<PAGE>
[LETTERHEAD OF MORGAN, LEWIS & BOCKIUS LLP APPEARS HERE]
Genentech, Inc.
December 30, 1998
Page 2
Based on the foregoing and subject to the qualifications and limitations set
forth below, we are of the opinion that:
1. The Company has been duly incorporated and is validly
existing and in good standing under the laws of the State of Delaware,
with all necessary corporate power and authority to enter into the
Agreement and the Affiliated Agreements, and to perform its obligations
thereunder.
2. The execution, delivery and performance of the Agreement
and the Affiliated Agreements have been duly authorized by all
necessary corporate action of the Company, and the Agreement and the
Affiliated Agreements have been duly executed and delivered by the
Company. Each of the Agreement and the Affiliated Agreements
constitutes a valid and binding obligation of the Company, enforceable
against the Company in accordance with its terms, subject to applicable
bankruptcy, insolvency, reorganization and similar laws affecting the
enforcement of creditors' rights generally, to the effect of rules of
law governing specific performance, injunctive relief or other
equitable remedies and to general principles of equity (regardless of
whether such enforceability is considered in a proceeding in equity or
an action at law).
3. The Shares to be issued and sold on the date hereof by the
Company pursuant to the Agreement have been duly authorized and, when
issued to and paid for by you in accordance with the terms of the
Agreement, will be validly issued, fully paid and non-assessable, free
of any liens or encumbrances and not subject to preemptive rights
pursuant to the Certificate of Incorporation or, to our knowledge,
other similar rights of the stockholders of the Company.
4. Assuming the accuracy of the representations of the
Investor contained in the Agreement and the Affiliated Agreements, and
assuming that offers and sales of the Shares have been made only in the
State of California, the offer and sale of the Shares and the delivery
of the Shares to you pursuant to the terms of the Agreement is exempt
from the registration requirements of the Securities Act of 1933, as
amended, and are exempt from the applicable requirements of the
securities laws of the State of California. We express no opinion as to
compliance with applicable anti-fraud statutes, rules or regulations of
any applicable law governing the issuance of securities.
5. The execution and delivery of each of the Agreement and
the Affiliated Agreements and the issuance and sale of the Shares on
the date hereof by the Company
<PAGE>
[LETTERHEAD OF MORGAN, LEWIS & BOCKIUS LLP APPEARS HERE]
Genentech, Inc.
December 30, 1998
Page 3
pursuant to the Agreement will not result in the violation by the
Company of its Certificate of Incorporation or Bylaws or, to our
knowledge, any federal or state statute, rule or regulation applicable
to the Company (other than federal or state securities laws, which are
specifically addressed elsewhere herein), and, to our knowledge, do not
contravene any order, writ, judgment, injunction, decree, determination
or award that has been entered against the Company, the violation of
which would materially and adversely affect the Company, its assets,
financial condition or operations, and no consent, approval,
authorization or order of, or filing with, any federal or California
court or governmental agency or body is required for the consummation
of the issuance and sale of the Shares on the date hereof by the
Company pursuant to the Agreement.
6. The authorized capital stock of the Company consists of
45,000,000 shares of Common Stock, par value $.002 per share, and
9,211,031 shares of Preferred Stock, par value $.0001 per share.
7. Except as disclosed in the Agreement and any documents
referred to therein and relying as to judgments in respect of
materiality on the advice of the executive officers of the Company, to
our knowledge, there is no action, proceeding or investigation pending
or threatened against the Company in any court or before any
governmental authority or arbitration board or tribunal that, if
adversely determined, would have a material adverse effect on the
Company taken as a whole or would question the validity of the
Agreement or the Affiliated Agreements, the Shares or any action taken
or to be taken pursuant to the Agreement or the Affiliated Agreements
or contemplated thereby.
The opinions set forth above are subject to the following
qualifications:
(A) Wherever we have stated we have assumed any matter, it is
intended to indicate that we have assumed such matter without making
any factual, legal or other inquiry or investigation, and without
expressing any opinion or conclusion of any kind concerning such
matter.
(B) Whenever a statement or opinion set forth herein is
qualified by "to our knowledge", or any similar phrase, it is intended
to indicate that, during the course of our representation of the
Company in the subject transaction and in prior transactions no
information that would give us current actual knowledge of the
inaccuracy of such statement has come to the attention of those
attorneys in this Firm who have rendered legal services in connection
with the representation described in the introductory
<PAGE>
[LETTERHEAD OF MORGAN,LEWIS & BOCKIUS LLP APPEARS HERE]
Genentech, Inc.
December 30, 1998
Page 4
paragraph of this opinion letter. However, we have not undertaken any
independent investigation to determine the accuracy of such statement
or opinion; no inference as to our knowledge of any matters bearing on
the accuracy of any such statement or opinion should be drawn from the
fact of our representation of the Company.
(C) We express no opinion with respect to the laws of any
jurisdiction other than the federal laws of the United States of
America, the laws of the Commonwealth of Pennsylvania and the Delaware
General Corporation Law (the "DGCL") and, with respect to our opinion
in paragraph 5, the California Corporate Securities Law of 1968, as
amended. Further, we express no opinion with respect to any federal or
state laws relating to tax and antitrust matters. With respect to
paragraph 5, our opinion regarding state securities laws is based
solely upon our examination of the latest unofficial compilations
available to us of the applicable statutes, if any, of the State of
California, and, in certain instances, the published rules and
regulations issued thereunder. Our opinion in paragraph 5 with respect
to state securities laws is further subject to broad discretionary
powers of the authorities administering the state securities laws to,
among other things, withdraw exemptions accorded by statute, to impose
additional requirements or to revoke or suspend at any time the
registration or qualification of securities for offering in their
respective jurisdictions. With respect to the State of California, we
have relied exclusively on information provided in the Agreement by the
Investor concerning the residency or principal place of business of the
Investor. Moreover, we have assumed that no form of general
solicitation or general advertising has been utilized in connection
with the sale of the Shares. We note that the Agreement and the
Ancillary Agreements recite that they are governed by the laws of the
State of New York. We have made no investigation of New York law nor
consulted with counsel admitted to practice law in the State of New
York. Instead, with your consent, we have assumed that the laws of the
State of New York are in all respects identical to the laws of the
Commonwealth of Pennsylvania.
(D) We express no opinion in Paragraph 2 as to the
enforceability of (i) the Option Agreement or Section 1.3 of the
Agreement or (ii) any provisions in the Agreement or any Affiliate
Agreement relating to indemnification, contribution or choice of
governing law.
(E) This opinion speaks only as of the date hereof and we do
not have, nor do we assume, any obligation to advise you of any changes
in facts or in the applicable laws of the Commonwealth of Pennsylvania
or the United States of America or the DGCL which may affect our
opinion.
<PAGE>
[LETTERHEAD OF MORGAN, LEWIS & BOCKIUS LLP APPEARS HERE]
Genentech, Inc.
December 30, 1998
Page 5
This opinion is solely for the benefit of the addressee hereof for use
in connection with the transactions contemplated by the Agreement and may not be
relied upon by any other person or for any other purpose without our express
written consent.
Very truly yours,
/s/ Morgan, Lewis & Bockius LLP
<PAGE>
* The confidential material contained herein has been omitted and filed
separately with the Comission.
SUPPLY AGREEMENT
----------------
BETWEEN
-------
ABBOTT LABORATORIES INC.
------------------------
AND
---
MAGAININ PHARMACEUTICALS INC.
-----------------------------
THIS AGREEMENT is made, effective as of January 1, 1999, (the
"Effective Date") by and between Abbott Laboratories Inc., an Illinois
corporation, having a principal place of business at 100 Abbott Park Road,
Abbott Park, Illinois 60064-3500 ("Abbott"), and Magainin Pharmaceuticals Inc.,
a Delaware corporation, having a principal place of business at 5110 Campus
Drive, Plymouth Meeting, Pennsylvania 19462 ("Magainin").
WHEREAS, Magainin is the owner of certain technology and patent rights
to pexiganan acetate;
WHEREAS, Magainin and Abbott have entered into a series of purchase
order agreements, including addendums thereto, and a stock issuance agreement,
pursuant to which Abbott has performed development activities leading to the
creation and maintenance of a Drug Master File (the "DMF") for Bulk Drug
Substance (the "Purchase Orders");
WHEREAS, Abbott possesses large scale facilities for the production of
commercial quantities of Bulk Drug Substance; and
WHEREAS, Magainin desires Abbott to produce for Magainin commercial
quantities of Bulk Drug Substance.
<PAGE>
NOW, THEREFORE, in consideration of the premises and the mutual
covenants and agreements contained herein, Magainin and Abbott agree as follows:
1. Definitions
-----------
As used in this Agreement, the following words and phrases shall have
the following meanings:
1.1 "Affiliate" of a party hereto means any entity which controls,
is controlled by, or is under common control with such party. For purposes of
this definition, a party shall be deemed to control another entity if it owns or
controls, directly or indirectly, at least fifty percent (50%) of the voting
equity of the other entity (or other comparable ownership interest for an entity
other than a corporation).
1.2 "Bulk Drug Substance" means the bulk form of pexiganan acetate
manufactured for Magainin by Abbott in accordance with the Bulk Drug
Specifications.
1.3 "Bulk Drug Specifications" means the written specifications
for Bulk Drug Substance set forth in Exhibit A as amended from time to time
pursuant to Subparagraph 6.1.
1.4 "Confidential Information" means all information disclosed
pursuant to this Agreement and the Purchase Orders in writing (or all
information disclosed orally, visually and/or in another tangible form that is
summarized in writing as to its general content within thirty (30) days after
original disclosure and identified as being confidential), except any portion
thereof that:
(i) is known to the recipient, as evidenced by its written records
before receipt thereof under this Agreement and the Purchase
Orders;
2
<PAGE>
(ii) is disclosed to the recipient without restriction after
acceptance of this Agreement by a third person who has the
right to make such disclosure;
(iii) is or becomes part of the public domain through no fault of
the recipient; or
(iv) is independently developed by or for the recipient by
individuals or entities who have not had access to
Confidential Information as evidenced by its written records.
1.5 "Contract Quarter" means each three (3)-month calendar period
beginning each January 1, April 1, July 1, and October 1, as the case may be, of
each Contract Year, However, the first Contract Quarter means the period
commencing on the first day of the first Contract Year and ending on the first
to occur of March 31, June 30, September 30, or December 31 of the first
Contract Year.
1.6 "Contract Year means the twelve month period commencing on the
Effective Date and each anniversary thereof.
1.7 "Effective Date" shall mean January 1, 1999.
1.8 "Requirements" means one hundred percent (100%) of the
commercial requirements for Bulk Drug Substance of Magainin, its Affiliates,
subsidiaries, assignees, licensees and sublicensees in the Territory.
3
<PAGE>
1.9 "Segments" means the series of assembly steps forming the
pexiganan molecule as referenced in the DMF and as described as follows:
- --------------------------------------------------------------------------------
Step ( ): (
)**
- --------------------------------------------------------------------------------
Step ( ): (
)**
- --------------------------------------------------------------------------------
Step ( ): (
)**
- --------------------------------------------------------------------------------
1.10 "Territory" means the entire world, except Europe.
2. Obligations of the Parties
--------------------------
2.1 Magainin shall purchase, and Abbott shall supply, ( ) *
kilograms of Bulk Drug Substance to be delivered during the first Contract Year.
2.2 On or before April 1, 1999, Magainin shall make an election
regarding its purchase obligations for the remainder of the term of this
Agreement, in accordance with Paragraph 2.2(a) or 2.2(b) as set forth below:
(a) Magainin shall purchase, and Abbott shall supply, a *
minimum of ( ) kilograms of Bulk Drug Substance to be delivered during the
second, third and fourth Contract Years, on delivery dates to be agreed upon by
the parties; or, alternatively
(b) Magainin shall elect to purchase its Requirements for the
remainder of Term.
* THE CONFIDENTIAL MATERIAL CONTAINED
HEREIN HAS BEEN OMITTED AND HAS BEEN
FILED SEPARATELY WITH THE COMMISSION
4
<PAGE>
2.3 Magainin hereby agrees to offer Abbott the opportunity to
provide a proposal for the development, manufacture and supply of pexiganan
acetate using recombinant technology based on capacity and ability, as mutually
agreed upon by both parties. If Abbott's proposal is equivalent in cost,
manufacturing and technical capability, facilities, delivery timing and scale to
any bona fide proposal received by Magainin Magainin and Abbott shall enter into
an agreement for the development, manufacture and supply of that pexiganan
acetate.
3. Price
-----
3.1 (a) The purchase price per gram for Bulk Drug Substance for
the first Contract Year shall be ( ) *
for the first ( ) *
kilograms, and ( ) *
for the next ( ), *
kilograms.
(b) The purchase price per gram for Bulk Drug Substance
purchased pursuant to Paragraph 2.2(a) hereof shall be ( ) *
for the next ( ) *
kilograms, as adjusted annually in accordance with C.P.l.-U.
(c) The purchase price per gram for Bulk Drug Substance
purchased pursuant to Paragraph 2.2(b), or for any additional kilograms of Bulk
Drug Substance beyond that purchased pursuant to Paragraph 2.2(a), shall be the
purchase price set forth in Exhibit B.
(d) Abbott shall not be obligated to store Bulk Drug Substance
beyond thirty (30) days from its manufacture. Notwithstanding the preceding
sentence should
* THE CONFIDENTIAL MATERIAL
CONTAINED HEREIN HAS BEEN
OMITTED AND HAS BEEN
FILED SEPARATELY WITH THE
COMMISSION
5
<PAGE>
Abbott consent to such storage, Magainin shall pay Abbott at a rate to be
negotiated between the parties, for any Bulk Drug Substance storage costs and/or
inventory carrying charges incurred by Abbott in excess of thirty (30) days
after the manufacture of the Bulk Drug Substance that is the subject of purchase
order.
3.2 Any federal, state, county or municipal sales or use tax,
excise or similar charge, or other tax assessment (other than that assessed
against income), governmental license fee or other charge lawfully assessed or
charged by governmental authorities on the manufacture, sale or transportation
of Bulk Drug Substance sold pursuant to this Agreement shall be paid by
Magainin.
3.3 If the Bulk Drug Specifications are modified hereunder or the
Bulk Drug Specifications must be modified by requirement of the FDA or other
regulatory agency (or its foreign equivalent), and such modification increases
Abbott's cost to manufacture Bulk Drug Substance, Abbott shall submit to
Magainin a revised price for Bulk Drug Substance which reflects such cost
increase and the adjusted price for Bulk Drug Substance shall be effective
immediately thereafter. If such modification results in the requirement to
reprocess and/or retest otherwise acceptable Bulk Drug, fifty percent (50%) of
any additional costs incurred by Abbott in such reprocessing, retesting and/or
regulatory filing shall be paid by Magainin upon submission by Abbott of
documentation of such costs. In the event that Magainin has previously accepted
Bulk Drug
6
<PAGE>
Substance pursuant to Article 7, Magainin shall pay one hundred percent (100%)
of any such additional costs.
3.4 If Magainin requests that Abbott perform (or the FDA or its
foreign equivalent requires) additional development work relating to Bulk Drug
Substance, including but not limited to work relating to modified dosage forms
of Bulk Drug Substance and validation of segments, the costs of such additional
work shall be paid for by Magainin.
3.5 Magainin shall pay Abbott for its direct costs pre-approved by
Magainin, unrelated to the costs associated with filing, maintaining and
updating the DMF as necessary, associated with (i) the FDA (and/or its foreign
equivalent) filing by Abbott requested by Magainin, in support of Magainin's
regulatory filings with respect to Bulk Drug Substance, and (ii) any work
requested by Magainin to produce and assemble documentation for Bulk Drug
Substance registrations both inside and outside the United States.
4. Term and Termination
--------------------
4.1 Except as provided in Subparagraph 4.2, this Agreement shall
commence on the Effective Date and shall terminate on the later of December 31,
2001 or the third anniversary of the commercial launch of finished product
containing Bulk Drug Substance (the "Termination Date"). Thereafter, except as
provided in Subparagraph 4.2, this Agreement shall continue automatically for
one-year periods until terminated upon not less than ninety (90) days' written
notice from either party to the other party. Notwithstanding the foregoing, in
the event that Magainin has not received FDA
7
<PAGE>
approval of finished product containing Bulk Drug Substance on or before January
1, 2000, Abbott shall have the option to terminate this Agreement upon thirty
(30) days' written notice. In the event that Magainin has not received FDA
approval of finished product containing Bulk Drug Substance on or before January
1, 2001, Magainin shall have the option to terminate this Agreement upon thirty
(30) days' written notice.
4.2 Upon the occurrence of the following events, either party may
terminate this Agreement by giving the other party sixty (60) days prior written
notice:
(i) Upon the bankruptcy or insolvency of the other party; or
(ii) Upon the material breach of any provision of this Agreement by
the other party if the breach is not remedied prior to the
expiration of such sixty (60) day notice period.
4.3 Termination, expiration, cancellation or abandonment of this
Agreement through any means and for any reason shall not relieve the parties of
any obligation accruing prior thereto, including, but not limited to, the
obligation to pay money or the requirement to supply or accept previously
ordered Bulk Drug Substance, and shall be without prejudice to the rights and
remedies of either party with respect to the antecedent breach of any of the
provisions of this Agreement. Further, Paragraphs 10, 11, 12, 13, 15, 18 and 25
shall survive the termination of this Agreement.
5. Forecasts and Orders
--------------------
5.1 Forecasting In the event that Magainin elects to purchase its
-----------
Requirements pursuant to Paragraph 2.2(b), Magainin shall give Abbott a forecast
of
8
<PAGE>
Magainin's estimated Requirements for the second Contract Year no later than
April 1, 1999, broken down by Contract Quarter. Such forecast shall be updated
by Magainin every six (6) months.
5.2 Firm Orders In the event that Magainin elects to purchase its
-----------
Requirements pursuant to Paragraph 2.2(b), the following provisions shall apply:
(a) On or before April 1, 1999, Magainin shall give Abbott a firm
purchase order of its Requirements for Bulk Drug Substance for the fourth
quarter of the second Contract Year.
(b) On or before the third Contract Quarter of the first Contract
Year, and each subsequent Contract Quarter thereafter, Magainin shall provide to
Abbott a firm purchase order for Bulk Drug Substance to be purchased by Magainin
during the next Contract Quarter not already covered by a firm purchase order.
(c) Each firm purchase order shall specify the quantity of Bulk
Drug Substance ordered and the required delivery date. Subject to the provisions
of this Subparagraph 5.2, Abbott shall use its reasonable best efforts to
deliver Bulk Drug Substance on or prior to the delivery date specified on the
order as received. Magainin shall use its reasonable best efforts to smooth the
quarterly requirements during each Contract Year.
(d) A firm purchase order shall not be cancellable once it is
issued to Abbott by Magainin.
9
<PAGE>
6. Manufacture of Bulk Drug Substance
----------------------------------
6.1 Abbott shall manufacture, or cause to be manufactured, Bulk
Drug Substance in compliance with cGMP's in accordance with all applicable
governmental regulations and in conformance with the Bulk Drug Specifications.
Bulk Drug Specifications may be modified from time to time by written agreement
of the parties without the necessity of amending this Agreement. Abbott shall
maintain all records as necessary and appropriate to demonstrate compliance with
cGMP's.
6.2 Abbott shall permit Magainin and SmithKline Beecham Inc., and,
if agreed and consented to by Abbott, Magainin licensees or sublicensees, or any
agent or consultant designated by Magainin in writing and who is under a binder
of confidentiality, access during reasonable business hours and after reasonable
notice to those areas of Abbott's manufacturing facilities where Bulk Drug
Substance is manufactured, stored and handled and to manufacturing records of
Bulk Drug Substance manufactured by Abbott solely for the purpose of Magainin
performing a quality assurance audit of such facilities and activities; provided
however that SmithKline Beecham, Inc., is under a binder of confidentiality.
Following such inspections, Magainin will submit a report to Abbott with
findings. If any items are identified as requiring follow-up action, then Abbott
shall respond to Magainin in writing within thirty (30) days of the receipt of
the report. Such response shall state actions Abbott plans to take to correct
any such items and the proposed timing(s) therefor, and shall set forth those
items that Abbott will not correct.
10
<PAGE>
6.3 Abbott shall maintain all regulatory and governmental permits,
licenses and approvals that may be necessary to manufacture and ship Bulk Drug
Substance to Magainin and, upon written request, will forward copies to Magainin
of any such permit, license or approval.
6.4 Abbott shall use its reasonable best efforts to report matters
regarding the manufacture of Bulk Drug Substance to the FDA or other appropriate
governmental authorities in accordance with pertinent laws and regulations.
Abbott shall notify Magainin as soon as reasonably possible of any such matter
and promptly furnish copies of such reports to Magainin.
6.5 Abbott shall be responsible for handling and responding to any
appropriate governmental agency inspections with respect to Bulk Drug Substance.
Abbott shall provide to Magainin copies of all material correspondence between
Abbott and any governmental agency in connection with any governmental
inspection related to Bulk Drug Substance. Abbott shall advise Magainin as soon
as reasonably possible of any requests by any governmental agency for such
inspections with respect to Bulk Drug Substance.
6.6 Abbott will not make material changes relating to the
manufacturing process of Bulk Drug Substance (as set forth in the DMF) or
relating to any of the raw materials, or controls used in the manufacture of
Bulk Drug Substance without prior written consent of Magainin. In the event that
Abbott believes that such change is necessary, Abbott will provide Magainin with
written notice detailing such proposed change. In no event shall any change be
implemented until Abbott has received written
11
<PAGE>
approval from Magainin. Such proposal shall not be unreasonably withheld. For
the purposes of this Subparagraph, a material change shall be considered a
change requiring prior approval by the FDA before it may be implemented, or a
change that adversely affects the delivery or quality of Bulk Drug Substance.
6.7 Abbott certifies it did not and will not knowingly use in any
capacity the services of any person, including any firm or individual, debarred
or subject to debarment under the Generic Drug Enforcement Act of 1992, amending
the Food, Drug and Cosmetic Act at 21 USC 335a. Abbott agrees to notify Magainin
immediately in the event any person providing services to Abbott under the scope
of this work of this Agreement is debarred or becomes subject to debarment.
6.8 Each shipment of Bulk Drug Substance delivered under this
Agreement shall be accompanied by a certificate of analysis ("COA") in the form
set forth in Exhibit C which shall specify that the delivered Bulk Drug
Substance conforms to the Bulk Drug Specifications. Such form shall be mutually
agreed upon by Abbott and Magainin. Magainin shall be under no obligation to
accept any shipment of Bulk Drug Substance without an accompanying COA.
6.9 Each party shall advise the other of any safety or toxicity
problem of which either party becomes aware regarding the Bulk Drug Substance
and any formulation containing Bulk Drug Substance within two (2) business days
of becoming aware of such problem.
12
<PAGE>
6.10 Abbott agrees to make reasonable efforts to improve the productivity,
efficiency, and quality of the process under which Bulk Drug Substance is
manufactured. Abbott and Magainin shall meet from time to time to review and
share ideas for these improvements.
6.11 Abbott shall use its reasonable best efforts to ensure that all Bulk
Drug Substance sold and shipped pursuant to this Agreement is manufactured in
accordance with all applicable Federal, state and local environmental, health
and safety laws and regulations in effect at the time and place of manufacture
of Bulk Drug Substance. Further, Abbott shall use its reasonable best efforts to
ensure that all waste, including but not limited to all hazardous waste,
generated in the manufacture of Bulk Drug Substance is disposed of in accordance
with all applicable Federal, state and local laws and regulations.
7. Acceptance of Bulk Drug Substance
---------------------------------
(a) Magainin shall have a period of forty-five (45) days from the date
of receipt of Bulk Drug Substance to inspect and reject any shipment of Bulk
Drug Substance. Magainin shall notify Abbott in writing of any claim relating to
damaged, defective or nonconforming Bulk Drug Substance or any shortage in
quantity of any shipment of Bulk Drug Substance within such forty-five (45) day
period. Failure to notify Abbott in writing of rejections within the forty-five
(45) day period shall constitute a waiver of all claims with respect to Bulk
Drug Substance delivered hereunder and, in any event, any use of the Bulk Drug
Substance by Magainin shall be deemed to mean satisfactory performance on the
part of Abbott. In the event of such rejection or
13
<PAGE>
shortage, Abbott shall replace the rejected Bulk Drug Substance or make up the
shortage within fifteen (15) days if replacement Bulk Drug Substance is
available, at no extra cost to Magainin, and shall make arrangements with
Magainin for the return of any rejected Bulk Drug Substance, such return
shipping charges to be paid by Abbott. No claims under this Paragraph 7 with
respect to delivered Bulk Drug Substance shall be greater in amount than the
purchase price of such Bulk Drug Substance. Nothing in this Paragraph 7 shall be
construed to limit the ability of Magainin to recover third party damages from
Abbott under Paragraph 11.
(b) In the event of a discrepancy between Magainin's and Abbott's test
results such that one party's results fall within the Bulk Drug Substance
Specifications and the other party's results fall outside the Bulk Drug
Substance Specification's, the parties shall cause an independent tester to
perform tests on samples of the allegedly defective Bulk Drug Substance using
the validated methods that were implemented by Abbott during the development of
Bulk Drug Substance. The independent tester's results shall be final and
binding, and all related costs and expenses incurred as a result of such
independent testing shall be borne by the erroneous party.
8. Shipment and Delivery
---------------------
8.1 Abbott shall prepare the Bulk Drug Substance for shipment and deliver
the Bulk Drug Substance to the carrier F.O.B. Abbott's manufacturing facility in
North Chicago, Illinois for delivery to ( ) *
* THE CONFIDENTIAL MATERIAL
14 CONTAINED HEREIN HAS BEEN
OMITTED AND HAS BEEN FILED
SEPARATELY WITH THE
COMMISSION
<PAGE>
( ), or a designate. Title and risk of *
loss for Bulk Drug Substance shall pass to Magainin at the time Abbott delivers
Bulk Drug Substance to the carrier designated by Magainin to transport Bulk Drug
Substance. All shipping costs shall be borne by Magainin.
8.2 Each delivery of Bulk Drug Substance shall be governed by the terms of
this Agreement, and none of the conflicting terms or conditions of Magainin's
purchase order form, Abbott's acknowledgment or invoice form shall be
applicable, except those specifying special shipping instructions.
8.3 All Bulk Drug Substance sold by Abbott to Magainin shall be free and
clear of all liens, claims and encumbrances.
9. Invoice
-------
(a) In regard to the first ( ) *
kilograms of Bulk Drug Substance shipped by Abbott to Magainin during the first
Contract Year, Abbott shall invoice Magainin upon shipment. Magainin shall pay
Abbott net seventy-five (75) days from the date of invoice.
(b) In regard to the remaining ( ) *
kilograms of Bulk Drug Substance shipped by Abbott to Magainin during the first
Contract Year, Abbott shall invoice Magainin as follows: (i) upon the completion
of Step ( ), a one time payment *
of (
); and, (ii) upon the shipment *
of each of the ( ) kilogram *
deliverables, ( ) **
* THE CONFIDENTIAL MATERIAL
15 CONTAINED HEREIN HAS BEEN
OMITTED AND HAS BEEN FILED
SEPARATELY WITH THE
COMMISSION
<PAGE>
( ) per shipment (for a *
total of ( ) *
shipments). Magainin shall pay Abbott net seventy-five (75) days from the date
of invoice.
(c) In regard to the purchases of Bulk Drug Substance made by Magainin
under Paragraph 2.2(a), Abbott shall bill Magainin according to the following
schedule:
Step in Manufacturing Process Percentage of Purchase Price Billed to
- ----------------------------- --------------------------------------
Magainin at Step Completion
---------------------------
Step( ) ( )% **
Step( ) ( )% **
Step( ) ( )% **
Abbott shall invoice Magainin for the remaining purchase price upon shipment of
Bulk Drug Substance. Magainin shall pay Abbott net forty-five (45) days from the
date of invoice.
(d) In regard to purchases of Bulk Drug Substance made by Magainin
pursuant to Section 2.2(b), Abbott shall invoice Magainin upon shipment.
Magainin shall pay Abbott net forty-five (45) days from the date of invoice.
(e) Magainin shall pay a late payment service charge of one and one-half
percent (1.5%) per month (or the highest amount allowed by law, if lower than
one and one-half percent (1.5%)) on all past-due amounts.
10. Warranties
----------
10.1 Abbott warrants that (i) Bulk Drug Substance delivered to Magainin
pursuant to this Agreement shall conform with the Bulk Drug Specifications and
shall be in compliance with applicable laws and regulations, (ii) Bulk Drug
Substance is and
* THE CONFIDENTIAL MATERIAL
16 CONTAINED HEREIN HAS BEEN
OMITTED AND HAS BEEN FILED
SEPARATELY WITH THE
COMMISSION
<PAGE>
shall be manufactured in accordance with cGMP and all applicable federal rules
and regulations, (iii) Bulk Drug Substance shall be free from defects in
materials and workmanship and shall not be adulterated or misbranded within the
meaning of the U.S. Federal Food, Drug and Cosmetic Act, and is not an article
which may not, under the Act, be introduced into interstate commerce, (iv) to
the best of Abbott's knowledge, any Confidential Information provided by Abbott
does not, and will not for the term hereof, infringe any patent or other
proprietary right of any third party, and (v) it owns or controls all of the
rights, title and interest in and to all Confidential Information provided by
Abbott to Magainin under this Agreement and the Purchase Orders. ABBOTT MAKES NO
OTHER WARRANTIES, EXPRESS OR IMPLIED, WITH RESPECT TO BULK DRUG SUBSTANCE. ALL
OTHER WARRANTIES, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION, THE IMPLIED
WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE ARE HEREBY
DISCLAIMED BY ABBOTT.
10.2 Magainin warrants to Abbott that (i) to the best of Magainin's
knowledge, any Confidential Information provided by Magainin to Abbott does not,
and will not for the term hereof, infringe any patent or other proprietary right
of any third party, (ii) that any Bulk Drug Substance shipped to Magainin shall
be stored in a manner that conforms to cGMP, and (iii) it owns or controls all
of the rights, title and interest in and to all Confidential Information
provided by Magainin to Abbott under this Agreement and the Purchase Orders.
17
<PAGE>
10.3 In no event shall either party be liable to the other party for
indirect, incidental or consequential damages, including without limitation,
lost revenues or profits. Nothing in this Subparagraph 10.3 shall abdicate the
rights of Abbott or Magainin to recover third party damages under Paragraph 11.
11. Indemnification
---------------
11.1 Magainin shall defend, indemnify and hold Abbott and its
Affiliates and their respective employees, directors, officers and agents
harmless against any liability, judgment, demand, action, suit, loss, damage,
cost and other expense (including reasonable attorney's fees) ("Liability")
resulting from any third party claims made or proceedings brought against Abbott
to the extent such Liability arises from (i) Magainin's negligence or willful
act or omission in the testing, use, manufacture, promotion, marketing, sale,
distribution, packaging, labeling, handling, or storage of Bulk Drug Substance
and/or formulations containing Bulk Drug Substance; (ii) Magainin's material
breach of this Agreement; (iii) any infringement set forth in Subparagraph 10.2;
(iv) the alleged release or threat of release of a hazardous substance at
either: (A) the place of manufacture of any finished product containing Bulk
Drug Substance, or (B) the place that any waste, including but not limited to
any hazardous waste, generated in the manufacture of any finished product
containing Bulk Drug Substance has been treated, stored or disposed; or (v)
Magainin's breach of any warranty set forth in Subparagraph 10.2.
11.2 Abbott shall defend, indemnify and hold Magainin and its
Affiliates and their respective employees, directors, officers and agents
harmless against any Liability
18
<PAGE>
resulting from any third party claims made or proceedings brought against
Magainin to the extent that such Liability arises from (i) Abbott's negligence
or willful act or omission in the manufacture, handling or storage of Bulk Drug
Substance; (ii) Abbott's material breach of this Agreement; (iii) any
infringement set forth in Subparagraph 10.1; (iv) the alleged release or threat
of release of a hazardous substance at either: (A) the place of manufacture of
Bulk Drug Substance, or (B) the place that any waste, including but not limited
to any hazardous waste, generated in the manufacture of Bulk Drug Substance has
been treated, stored or disposed; or (v) Abbott's breach of any warranty set
forth in Subparagraph 10.1.
11.3 Each party shall notify the other promptly of any threatened or
pending claim or proceeding covered by any of the above Subparagraphs in this
Paragraph 11 and shall include sufficient information to enable the other party
to assess the facts. Each party shall cooperate fully with the other party in
the defense of all such claims. No settlement or compromise shall be binding on
a party hereto without its prior written consent.
12. Proprietary Ownership of Technology and License Grants
------------------------------------------------------
12.1 Abbott shall own any discovery or invention, whether or not
patentable (an "Invention"), consisting of a solution phase process or any other
process of manufacturing Bulk Drug Substance and all plans, procedures,
specifications, technology, know-how, and other information reasonably necessary
for the practice of the Invention that is conceived and reduced to practice by
Abbott personnel in the conduct of the work hereunder, and under all prior
Purchase Orders. Abbott and
19
<PAGE>
Magainin shall jointly own any Invention consisting of a solution phase process
or any other process of manufacturing Bulk Drug Substance that is conceived or
reduced to practice hereunder and under all prior Purchase Orders as to which at
least one Abbott employee and at least one Magainin employee are co-inventors.
Magainin shall exclusively own (a) any Invention consisting of improvements,
modifications, enhancements, refinements or new uses of Bulk Drug Substance, and
(b) subject to the first two sentences of this Paragraph 12, any Magainin
Confidential Information, that is conceived or reduced to practice in the
conduct of the work hereunder, regardless of which party conceived or reduced
such Invention to practice.
12.2 In the event that Magainin seeks a license to Abbott's Inventions
prior to the second anniversary of the Termination Date, then Magainin shall
make payments in accordance with the following schedule:
Termination Date/License Grant Payment Due Date
------------------------------ -------
On or before the Termination Date ( ) ( ) at time of **
license grant,
( ) every three *
(3) months
thereafter
After the Termination Date but ( ) ( ) at time of **
on or before the Second license grant,
Anniversary of the Termination Date ( ) every three *
months thereafter
Anytime after the Second ( ) ( ) at time of **
Anniversary of the Termination license grant
Date
* THE CONFIDENTIAL MATERIAL
20 CONTAINED HEREIN HAS BEEN
OMITTED AND HAS BEEN FILED
SEPARATELY WITH THE
COMMISSION
<PAGE>
Subject to the payment terms set forth above, as applicable, Magainin shall need
no further license from Abbott for the use of Abbott Inventions.
12.3 If the parties terminate the Supply Agreement, Abbott will assist
Magainin with regard to Magainin's transition to another supplier or to internal
production of Bulk Drug Substance, as the case may be, at Abbott's sole cost,
for a period not to exceed six (6) man months. Any additional assistance
requested by Magainin shall be paid for by Magainin.
13. Confidential Information
------------------------
Neither party shall use or disclose any Confidential Information received
by it pursuant to this Agreement without the prior written consent of the other
party. Except as provided in the following sentence, nothing contained in this
Paragraph shall be construed to restrict the parties from disclosing
Confidential Information as is reasonably necessary to perform acts permitted by
this Agreement. However, if either party is required or feels it necessary to
disclose any Confidential Information received by it pursuant to this Agreement
(whether by audit or otherwise) to any third party or governmental agency in
compliance with any federal, state and/or local laws and/or regulations, or
pursuant to an order of a court of competent jurisdiction, the disclosing party
shall notify the party owning such Confidential Information immediately, prior
to any such disclosure, in order to enable the owning party to protect its
Confidential Information. In any event, the disclosing party shall make any
disclosures of Confidential Information received by it pursuant to this
Agreement only to the extent required, and only to such persons who have a need
to know. The obligations of the
21
<PAGE>
parties relating to Confidential Information shall expire five (5) years after
termination of this Agreement.
14. Force Majeure
-------------
Any delay in the performance of any of the duties or obligations of any
party (except the payment of money due hereunder) caused by an event outside the
affected party's reasonable control shall not be considered a breach of this
Agreement, and unless provided to the contrary herein, the time required for
performance shall be extended for a period equal to the period of such delay.
Such events shall include without limitation, acts of God; acts of the public
enemy; insurrections; riots; injunctions; embargoes; labor disputes, including
strikes, lockouts, job actions, or boycotts; fires; explosions; floods;
earthquakes; shortages of material or energy; delays in the delivery of raw
materials; or other unforeseeable causes beyond the reasonable control and
without the fault or negligence of the party so affected. The party so affected
shall give prompt notice to the other party of such cause, and shall take
whatever reasonable steps are necessary to relieve the effect of such cause as
rapidly as reasonably possible.
15. Recalls
-------
In the event (i) any government authority issues a request, directive
or order that the Bulk Drug Substance or Product be recalled, or (ii) a court of
competent jurisdiction orders such a recall, or (iii) Magainin reasonably
determines after consultation with Abbott that the Bulk Drug Substance or
Product should be recalled, the parties shall take all appropriate corrective
actions. In the event that such recall results from the
22
<PAGE>
failure of the Bulk Drug Substance to meet the Bulk Drug Specifications, and
such failure could not reasonably be detected by Magainin within the forty-five
(45) day acceptance period set forth in Paragraph 7, Abbott shall be responsible
for all expenses of the recall. In all other cases, Magainin shall be
responsible for the expense of recall, including the expense or service fee
associated with the representatives' time. For the purposes of this Agreement,
the expenses of recall shall include, without limitation, the expense of
notification and destruction or return of the recalled Bulk Drug Substance or
Product, but not the expense or service fee associated with the representatives'
time which shall in all cases be borne by Magainin. The remedy set forth above
shall constitute the sole remedy under this Paragraph 15.
16. Notices
-------
All notices hereunder shall be in writing and shall be delivered
personally, mailed by overnight delivery, registered or certified mail, postage
prepaid, mailed by express mail service or given by facsimile, to the following
addresses of the respective parties:
If to Abbott: Abbott Laboratories
President
Chemical and Agricultural Products Division
Department 390, Building Al
1401 Sheridan Road
North Chicago, IL 60064-4000
Fax Number: 847/938-2315
23
<PAGE>
with copy to: Abbott Laboratories
Senior Vice President and General Counsel
Department 364, Building AP6D
100 Abbott Park Road
Abbott Park, IL 60064-3500
Fax Number: 847/938-6277
If to Magainin: Magainin Pharmaceuticals, Inc.
5110 Campus Drive
Plymouth Meeting, Pennsylvania 19462
Attn: Chief Executive Officer
Fax Number: 610/941-5399
Notices shall be effective upon receipt if personally delivered, on the third
business day following the date of mailing if sent by certified or registered
mail, and on the second business day following the date of delivery to the
express mail service if sent by express mail, or the date of transmission if
sent by facsimile. A party may change its address listed above by notice to the
other party.
17. Binding Effect
--------------
This Agreement shall be binding upon and shall inure to the benefit of
the parties hereto and their respective assigns and successors in interest.
18. Applicable Law
--------------
This Agreement shall be construed, interpreted and governed by the laws
of the State of Illinois, except for choice of law rules. Any controversy or
claim arising out of relating to this Agreement, or the breach thereof, shall be
resolved by the alternative
24
<PAGE>
dispute resolution process described in Exhibit D; provided, however, that each
party may seek injunctive relief to prevent the breach of the other party's
obligations under this Agreement.
19. Assignment
----------
Neither party shall assign this Agreement or any part thereof without
the prior written consent of the other party; provided, however, that this
Agreement may be assigned by either party to a third party purchaser in the
event of an acquisition of at least fifty (50%) percent of Magainin. Any
permitted assignee shall assume all obligations of its assignor under this
Agreement. No assignment shall relieve any party of responsibility for the
performance of any accrued obligation that such party then has hereunder.
20. Entire Agreement
----------------
20.1 Except as provided in Subparagraph 20.2 below this Supply
Agreement constitutes the entire agreement between the parties concerning the
subject matter hereof and supersedes all written or oral prior agreements or
understandings with respect thereto. No party shall claim any amendment,
acknowledgment or acceptance of purchase order forms or otherwise, unless in
writing signed by an authorized representative of each party.
20.2 This Agreement shall not supersede or replace any of the
Purchase Orders, all of which shall be interpreted consistently with this
Agreement.
25
<PAGE>
21. Severability
------------
This Agreement is subject to the restrictions, limitations, terms and
conditions of all applicable governmental regulations, approvals and clearances.
If any term or provision of this Agreement shall for any reason be held invalid,
illegal or unenforceable in any respect, such invalidity, illegality or
unenforceability shall not affect any other term or provision hereof, and this
Agreement shall be interpreted and construed as if such term or provision, to
the extent the same shall have been held to be invalid, illegal or
unenforceable, had never been contained herein.
22. Waiver
------
No waiver or modification of any of the terms of this Agreement shall
be valid unless in writing and signed by an authorized representative of each
party hereto. Failure by either party to enforce any rights under this Agreement
shall not be construed as a waiver of such rights nor shall a waiver by either
party in one or more instances be construed as constituting a continuing waiver
or as a waiver in other instances.
23. Exhibits
--------
All Exhibits referenced herein are hereby made a part of this
Agreement.
24. Counterparts
------------
This Agreement may be executed in any number of separate counterparts,
each of which shall be deemed to be an original, but that together shall
constitute one and the same instrument.
26
<PAGE>
25. No Disclosure of Agreement
--------------------------
Neither party shall disclose the provisions of this Agreement without
the prior written approval of the other party. Neither party shall use the name
of the other party in any publicity or advertising without the other party's
prior written consent, except as may be required by law.
IN WITNESS WHEREOF, the parties have caused this Agreement to be
executed by their duly authorized representatives on the later date written
below.
ABBOTT LABORATORIES INC. MAGAININ PHARMACEUTICALS INC.
By: [SIGNATURE APPEARS HERE] By: /s/ M. Dougherty
--------------------------- ---------------------------
Title: DIV. VP. Title: PRES., CEO
------------------------ ------------------------
Date: 12/22/98 Date: 12/18/98
------------------------- -------------------------
<PAGE>
Exhibit A
---------
Specifications
***
* THE CONFIDENTIAL MATERIAL CONTAINED
HEREIN HAS BEEN OMITTED AND HAS BEEN
FILED SEPARATELY WITH THE COMMISSION
<PAGE>
Exhibit B
---------
Pricing
Annual Volume Commitment (Kilograms) *Price per Gram
------------------------------------ ---------------
( ) ( ) **
( ) ( ) **
( ) ( ) **
( ) ( ) **
( ) ( ) **
( ) ( ) **
*Annual price increases based on CPI-U
* THE CONFIDENTIAL MATERIAL
CONTAINED HEREIN HAS BEEN OMITTED
AND HAS BEEN FILED SEPARATELY WITH
THE COMMISSION
<PAGE>
ABBOTT LABORATORIES
Chemical and Agricultural Products Division Exhibit C
North Chicago Illinois 60064-4000 ---------
TEL: 1-800-323-9597 FAX: 1-847-938-6035
================================================================================
Quality Health Care Worldwide
CERTIFICATE OF ANALYSIS
22--Oct--1996
***
The undersigned certifies this to be a true copy of the results of tests
and assays conducted by ABBOTT LABORATORIES.
/s/ Susan Kendzior
Susan Kendzior
Quality Assurance
* THE CONFIDENTIAL MATERIAL
CONTAINED HEREIN HAS BEEN
OMITTED AND HAS BEEN FILED
SEPARATELY WITH THE
COMMISSION
<PAGE>
Exhibit D
---------
Alternative Dispute Resolution
The parties recognize that a bona fide dispute as to certain matters may arise
from time to time during the term of this Agreement that relates to either
party's rights and/or obligations. To have such a dispute resolved by this
Alternative Dispute Resolution ("ADR") provision, a party first must send
written notice of the dispute to the other party for attempted resolution by
good faith negotiations between their respective presidents (or their
equivalents) of the affected subsidiaries, divisions, or business units within
twenty-eight (28) days after such notice is received (all references to "days"
in this ADR provision are to calendar days).
If the matter has not been resolved within twenty-eight (28) days of the notice
of dispute, or if the parties fail to meet within such twenty-eight (28) days,
either party may initiate an ADR proceeding as provided herein. The parties
shall have the right to be represented by counsel in such a proceeding.
1. To begin an ADR proceeding, a party shall provide written notice to the
other party of the issues to be resolved by ADR. Within fourteen (14) days
after its receipt of such notice, the other party may, by written notice to
the party initiating the ADR, add additional issues to be resolved within
the same ADR.
2. Within twenty-one (21) days following receipt of the original ADR notice,
the parties shall select a mutually acceptable neutral to preside in the
resolution of any disputes in this ADR proceeding. If the parties are
unable to agree on a mutually acceptable neutral within such period, either
party may request the President of the CPR Institute for Dispute Resolution
("CPR") 366 Madison Avenue, 14th Floor, New York, New York 10017, to select
a neutral pursuant to the following procedures:
(a) The CPR shall submit to the parties a list of not less than five (5)
candidates within fourteen (14) days after receipt of the request,
along with a Curriculum Vitae for each candidate. No candidate shall
be an employee, director, or shareholder of either party or any of
their subsidiaries or affiliates.
(b) Such list shall include a statement of disclosure by each candidate of
any circumstances likely to affect his or her impartiality.
<PAGE>
(c) Each party shall number the candidates in order of preference (with
the number one (1) signifying the greatest preference) and shall
deliver the list to the CPR within seven (7) days following receipt of
the list of candidates. If a party believes a conflict of interest
exists regarding any of the candidates, that party shall provide a
written explanation of the conflict to the CPR along with its list
showing its order of preference for the candidates. Any party failing
to return a list of preferences on time shall be deemed to have no
order of preference.
(d) If the parties collectively have identified fewer than three (3)
candidates deemed to have conflicts, the CPR immediately shall
designate as the neutral the candidate for whom the parties
collectively have indicated the greatest preference. If a tie should
result between two candidates, the CPR may designate either candidate.
If the parties collectively have identified three (3) or more
candidates deemed to have conflicts, the CPR shall review the
explanations regarding conflicts and, in its sole discretion, may
either (i) immediately designate as the neutral the candidate for whom
the parties collectively have indicated the greatest preference, or
(ii) issue a new list of not less than five (5) candidates, in which
case the procedures set forth in Sections 2(a) - 2(d) shall be
repeated.
3. No earlier than twenty-eight (28) days or later than fifty-six (56) days
after selection, the neutral shall hold a hearing to resolve each of the
issues identified by the parties. The ADR proceeding shall take place at a
location agreed upon by the parties. If the parties cannot agree, the
neutral shall designate a location other than the principal place of
business of either party or any of their subsidiaries or affiliates.
4. At least seven (7) days prior to the hearing, each party shall submit the
following to the other party and the neutral:
(a) a copy of all exhibits on which such party intends to rely in any oral
or written presentation to the neutral;
(b) a list of any witnesses such party intends to call at the hearing, and
a short summary of the anticipated testimony of each witness;
(c) a proposed ruling on each issue to be resolved, together with a
request for a specific damage award or other remedy for each issue.
The proposed rulings and remedies shall not contain any recitation of
the facts or any legal arguments and shall not exceed one (1) page per
issue.
<PAGE>
(d) a brief in support of such party's proposed rulings and remedies,
provided that the brief shall not exceed twenty (20) pages. This page
limitation shall apply regardless of the number of issues raised in
the ADR proceeding. Except as expressly set forth in Sections 4(a) -
4(d), no discovery shall be required or permitted by any means,
including depositions, interrogatories, requests for admissions, or
production of documents.
5. The hearing shall be conducted on two (2) consecutive days and shall be
governed by the following rules:
(a) Each party shall be entitled to five (5) hours of hearing time to
present its case. The neutral shall determine whether each party has
had the five (5) hours to which it is entitled.
(b) Each party shall be entitled, but not required, to make an opening
statement, to present regular and rebuttal testimony, documents or
other evidence, to cross-examine witnesses, and to make a closing
argument. Cross-examination of witnesses shall occur immediately after
their direct testimony, and cross-examination time shall be charged
against the party conducting the cross-examination.
(c) The party initiating the ADR shall begin the hearing and, if it
chooses to make an opening statement, shall address not only issues it
raised but also any issues raised by the responding party. The
responding party, if it chooses to make an opening statement, also
shall address all issues raised in the ADR. Thereafter, the
presentation of regular and rebuttal testimony and documents, other
evidence, and closing arguments shall proceed in the same sequence.
(d) Except when testifying, witnesses shall be excluded from the hearing
until closing arguments.
(e) Settlement negotiations, including any statements made therein, shall
not be admissible under any circumstances. Affidavits prepared for
purposes of the ADR hearing also shall not be admissible. As to all
other matters, the neutral shall have sole discretion regarding the
admissibility of any evidence.
6. Within seven (7) days following completion of the hearing, each party may
submit to the other party and the neutral a post-hearing brief in support
of its proposed rulings and remedies, provided that such brief shall not
contain or discuss any new evidence and shall not exceed ten (10) pages.
This page limitation shall apply regardless of the number of issues raised
in the ADR proceeding.
<PAGE>
7. The neutral shall rule on each disputed issue within fourteen (14) days
following completion of the hearing. Such ruling shall adopt in its
entirety the proposed ruling and remedy of one of the parties on each
disputed issue but may adopt one party's proposed rulings and remedies on
some issues and the other party's proposed rulings and remedies on other
issues. The neutral shall not issue any written opinion or otherwise
explain the basis of the ruling.
8. The neutral shall be paid a reasonable fee plus expenses. These fees and
expenses, along with the reasonable legal fees and expenses of the
prevailing party (including all expert witness fees and expenses), the fees
and expenses of a court reporter, and any expenses for a hearing room,
shall be paid as follows:
(a) If the neutral rules in favor of one party on all disputed issues in
the ADR, the losing party shall pay 100% of such fees and expenses.
(b) If the neutral rules in favor of one party on some issues and the
other party on other issues, the neutral shall issue with the rulings
a written determination as to how such fees and expenses shall be
allocated between the parties. The neutral shall allocate fees and
expenses in a way that bears a reasonable relationship to the outcome
of the ADR, with the party prevailing on more issues, or on issues of
greater value or gravity, recovering a relatively larger share of its
legal fees and expenses.
9. The rulings of the neutral and the allocation of fees and expenses shall be
binding, non-reviewable, and non-appealable, and may be entered as a final
judgment in any court having jurisdiction.
10. Except as provided in Section 9 or as required by law, the existence of the
dispute, any settlement negotiations, the ADR hearing, any submissions
(including exhibits, testimony, proposed rulings, and briefs), and the
rulings shall be deemed Confidential Information. The neutral shall have
the authority to impose sanctions for unauthorized disclosure of
Confidential Information.
